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Abstract 
 
Epigenetics can be defined as the set of sequence independent processes that produces 
heritable changes in cellular information. These chromatin-based events such as 
covalent modification of DNA and histone tails are laid down by the co-ordinated 
action of chromatin modifying enzymes, thus altering the organisation of chromatin 
and its accessibility to the transcriptional machinery. Our understanding of epigenetic 
intricacies has considerably increased over the last decade owing to rapid development 
of genomic and proteomic technologies. This has resulted in huge surge in the 
generation of epigenomics data. Integrative analysis of these epigenomics datasets 
provides holistic view on the interplay of various epigenetic components and possible 
aberration in patterns in specific biological or disease states. Although, there are 
numerous computational tools available catering individually to each epigenomic data-
type, a comprehensive computational framework for integrated exploratory analysis of 
these datasets was missing. We developed a suite of R packages methylPipe and 
compEpiTools that can efficiently handle whole genome base-resolution DNA 
methylation datasets and effortlessly integrate them with other epigenomics data.  We 
applied these methods to the study of epigenomics landscape in B-cell lymphoma 
identifying a putative set of tumor suppressor genes. Moreover, we also applied these 
methods to explore possible associations between m6A RNA methylation, epigenetic 
marks and regulatory proteins.   
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Introduction 
	  
Biologists have been puzzled for decades to know how a single genome contained in a 
single cell fertilized egg can give rise to hundreds of different cell types found in an 
embryo or adult. Further, how it creates from the same genetic book of instructions 
different functional outcomes and phenotype for the cells. This outcome is attributed to 
the additional information on top of that genetic one, which allows the formation of 
each individual cell type, despite existence of the same genetic code within them. 
‘Epigenetics’ a term coined by Edward Waddington[1] in 1942 is used to describe this 
additional layer of information on top of the genetic information. It is the study of 
mitotically heritable changes in gene expression that occur without changes to the DNA 
sequence. This epigenetic information allows the development and differentiation of the 
hundreds of different cell types, all from the same set of instructions[2, 3]. The genes 
that are expressed within each cell define its identity. Each cell type can actually express 
only a restricted subset of genes. In mammalian genome nowhere near 25000 (total) 
genes are expressed in each cell type, at each time. Each cell type expresses a 
combination of a few thousand genes out of the all the possible permutations and this 
particular set of expressed genes within each cell type enables the phenotype and the 
function of each cell.  
Hence the question arises, if the genes that are expressed define each cell type, 
how can a different set of genes be expressed within each cell? How does the cell realize 
which genes to express? This is made possible by a combination of two things. Firstly, it 
is due to the activity of transcription factors that are specific for each cell lineage[4]. 
These proteins with sequence specificity in their binding to DNA, bind to the promoters 
of genes to activate or repress the expression of specific targets. But these lineage 
	   10	  
specific transcription factors do not act alone. They need to work within the context of 
broader information that comes in the form of epigenetic marks within the genome.  
Epigenetic marks provide structure to the chromosome by marking the 
beginning, center and the end of the whole chromosome. They alter how the gene 
information is read; so there are marks that are associated with both active (expressed) 
and inactive (silent) genes. So the reason for each cell type to have different sets of 
expressed genes is partly because of the epigenetic marks that are found on the genes 
that are expressed, or not being expressed. Hence, the epigenetic control allows or 
permits the differential expression of genes within each cellular lineage, and therefore 
permits the development and differentiation of hundreds of cell types from the single 
genome. 
 
1.1  Epigenetics in development 
 
Epigenetic control plays an important role throughout the development of an 
organism[5]. The diagram [Figure 1] depicts the epigenetic control during development 
from the single cell fertilized egg (zygote), pre-implantation to post-implantation 
development. In each stage of this life cycle different genomic regions are marked by 
particular epigenetic marks according to their particular functions. These epigenetic 
marks laid throughout development ensure accuracy and maintenance of the cellular 
identity. However, these marks are naturally removed globally two times during the 
life cycle of mammals. The first stage is the pre-implantation stage when the paternal 
(sperm) and maternal (oocyte) epigenomes are reset to form zygote. During this phase, 
DNA methylation and histone marks are removed throughout the genome. The 
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paternal genome is actively demethylated whereas the maternal genome is passively 
de-methylated (epigenetic marks are lost upon replication)[5]. This reaches a low at the 
blastocyst stage, just before the implantation. Thereafter, epigenetic marks are re-
established in lineage specific manner. Concurrently, individual lineage specific 
processes undergo active re-modelling of these epigenetic marks. The second global 
remodeling of epigenetic marks happens during primordial germ cells development. 
These cells primed for somatic fate must be epigenetically remodeled to ensure 
totipotency in the next generation[6]. In the midst of this epigenetic resetting, parts of 
the genome particularly repeat, transposons and imprinted loci (during pre-
implantation) remain unaltered[5]. 
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This prevents activation of retrotranposons and maintains chromosomal stability to 
ensure proper development. When this ubiquitously important process of epigenetic 
control goes wrong, it results in a wide array of different disorders like imprinting 
disorders, embryonic lethality and several types of tumors[7]. 
Figure 1: Epigenetic programming and reprogramming during the mouse life cycle. 
Cantone & Fisher, Nature Structural & Molecular Biology 20, 282–289 (2013) 
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1.2  Chromosome structure 
 
Chromatin inside the nucleus consists of DNA wrapped around histone proteins. This 
packaging compresses roughly two meters of DNA within the nucleus down to a ten-
micrometer diameter. As DNA is accessed several times, this process must result in an 
ordered structure. The accessibility to the DNA is required during transcription as well 
as during DNA replication and repair mechanisms. Thus, how tightly the chromatin is 
packed relates to the need for accessibility. This further determines the accessibility to 
transcription factors and the RNA Polymerase. If the DNA is tightly packed around the 
histone proteins then it makes it inaccessible to the RNA Polymerase and the 
transcription factors. Consequently, it's less likely to be active or expressed and vice- 
versa. 
The smallest unit of the DNA combined with histones is known as the 
nucleosome. It consists of a DNA wrapped around a histone octamer [Figure 2]. These 8 
units are made up of 2 units each of histones H2A, H2B, H3, and H4. Together they 
make up the 8 histones molecules acting like a spool for the DNA. On the outside 
histone H1 locks together that spool and holds the DNA in place. The reason that this 
interaction can occur between the histones and the DNA is because histones are rich in 
positively charged amino acids, particularly lysine and arginine. Positively charged 
histones and negatively charged DNA interact via electrostatic interaction. The N-
terminal tails of the histones tend to protrude out of the nucleosome and these 
protrusions are important for the modification of histones.  
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The nucleosome has a bead-in-a-string structure. It can be further condensed into a 
higher order chromatin packaging into a 30 nanometer fiber via interaction between 
histone H1 molecules. If scaffolding proteins are added on top of this 30-nanometer 
fiber, it becomes an interphase chromosome. Subsequently, it is compacted further 
down at metaphase by adding a final layer of scaffolding proteins [Figure 3]. There are 
different forms of chromatin specially open and closed chromatin. Closed chromatin is 
known as heterochromatin whereas open chromatin is called euchromatin. 
Heterochromatin is further classified as facultative heterochromatin and constitutive 
heterochromatin. Facultative heterochromatin can differ between cell type thereby 
constituting tissue specific things that can be expressed in one cell type and not another. 
 
 
 
Figure 2: Histone proteins. 
Adapted from Spreadscienceblog 
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On the contrary, constitutive heterochromatin is stable in every cell and performs a 
structural role (telomeres and centromeres). Epigenetic marks at the beginning, end and 
even at center of the chromosomes is constitutive heterochromatin. This helps to 
maintain the structural integrity of the genome. Each of these different types of 
chromatin has a distinct set of epigenetic marks.  The following section explains specific 
epigenetic modifications and their functional consequence. 
Figure 3: Chromosome compaction. 
(https://beyondthedish.wordpress.com/tag/histone-proteins/ 
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1.3  Histone modifications 
 
Histone proteins are one of the most important components of the epigenetics. These 
proteins are embellished by a number of post-translational histone modifications (called 
histone marks) such as acetylation, methylation, phosphorylation, SUMOylation and 
many more[8, 9]. These modifications tend to occur almost exclusively on the N-
terminal tails of the histones that protrude out from the nucleosome. There are a 
plethora of different places where these histone modifications can occur with a variety 
of different residue[10] [Figure 4]. 
Each histone tail modification is associated with a different function. Histone 
methylation and acetylation are the best characterized of these histone modifications. 
Histone methylation, that occurs as mono, di or tri (number of added methyl group) at 
lysine or arginine residue tends to be associated with transcription[11]. Histone 
acetylation on the other hand is universally associated with actively transcribed 
gene[12]. Histones are acetylated by the histone acetyltransferases (HATs)[13] and these 
marks are removed by histone deacetylases (HDACs)[14]. Further, histone methylation 
can be associated either with gene activity or gene inactivity depending on the context. 
While H3K4me3 methylation marks active promoters, H3K9 methylation is mostly 
associated with constitutive heterochromatin[15]. H3K27 methylation is also an inactive 
mark spread over the entire gene but associated with facultative heterochromatin[15]. 
H3K27methylation is carried out by EZH2 that is part of polycomb repressive complex 
2 (PRC2)[16]. Since this is found in facultative heterochromatin EZH2 and PRC2 
complex plays an important role in tissue specific gene silencing[17].  
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Figure 4: Histone modifications. 
Marks et al, Nature Reviews Cancer 1, 194-202 (December 2001) 
 
 
Histone modifications are recognized by specific effector proteins including 
chromatin regulators (CRs) to cause the desired downstream changes. This binding by 
different proteins under different contexts results in diverse functional outcomes. For 
example H3K4 methylation, H3K9 methylation and H3K27 methylation all are bound 
by a chromodomain. But each has specificity for particular residues: CHD1 binds H3K4 
(me), HP1 binds H3K9 (me) and CBX2 binds H3K27 (me). CHD1 is an ATP dependent 
chromatin remodeler that can open or condense the nucleosomes[18]. On the other 
hand, HP1 can bring in DNA methyltransferase (DNMT1) that methylates the 
neighbouring CpG di-nucleotides[19] or recruit histone methyl-transferases to enable 
spreading of the H3K9 methylation to other neighbouring nucleosomes[20]. Further, 
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CBX2 is part of another polycomb repressive complex, PRC1[21]. To summarize, 
euchromatin is associated with high levels of acetylation and tri-methylated H3K4 or 
H3K36[22]. On the other hand, heterochromatin is associated with low levels of 
acetylation and high levels of H3K9 or H3K27 methylation[22]. However, an interesting 
case has emerged of co-existence of H4K4me3 and H3K27me3 (bivalent domains) that 
mark the developmentally important genes in embryonic stem cells[23]. These domains 
have crucial implications in maintaining totipotency in stem cells and are lost further 
upon cell differentiation. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Histone marks cross talk with other epigenetic marks such as DNA methylation 
has been well studied [Figure 5]. The studies show the interplay of DNMT3L and H3K4 
during early development[24]. According to this, DNMT3L interacts with histone H3 
Figure 5: Links between DNA methylation and histone modification. 
Adapted from En li, Nature Reviews Genetics 3, 662-673 (September 2002) 
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tails to recruit DNMT3A and cause de novo DNA methylation[24, 25]. However, this 
interaction is strongly inhibited at regions marked by H3K4me3 (active mark). 
Moreover, histone methyltransferase G9a (which catalyzes H3K9 methylation) can 
recruit DNMTs to perform targeted de-novo methylation to lock the silenced state 
established by the repressive histone marks[26, 27]. On the other hand, the instance of 
DNA methylation directed H3K9 di-methylation via recruitment of MeCP2 shows the 
bi-directionality of this cross talk[28–30]. Moreover, Strahl and Allis proposed “the 
histone code” hypothesis postulating that these multiple histone modifications act in a 
sequential or combinatorial manner to bring about distinct downstream changes[31]. 
Although experimental support for this hypothesis is lacking, many studies observing 
the recognition of multiple chromatin modification simultaneously by chromatin 
regulators supports this idea[32, 33]. Computational methods such as ChromaSig[34]  
and ChromHMM[35] have been developed to identify combinatorial association of 
these histone modifications. These methods could classify chromatin states according to 
the functional genomic constituents. The advancement of the high throughput 
sequencing technologies (leading to wealth of data) and computational methods has 
significantly increased our understanding of the combinatorial complexity of histone 
modifications. 
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1.4  DNA methylation 
 
1.4.1  Laying and erasing DNA methylation 
 
The covalent modification of DNA (DNA methylation) is one of the most extensively 
studied epigenetic marks in eukaryotes. It involves the covalent modification of 
cytosine bases of genomic DNA to 5-methylcytosine upon addition of a methyl group, 
catalysed by DNA methyl-transferase (DNMT) enzymes. The enzymes DNMT3A and 
DNMT3B lay down the methylation in a de novo fashion during development[36]. 
During cell division when the DNA is replicated, another DNA methyltransferase 
enzyme (DNMT1) specifically recognizes hemi-methylated DNA[37]. DNMT1 then lays 
down methylation on the un-methylated strand to restore fully methylated CpG 
dinucleotide. Hence, DNA methylation can be a stable epigenetic mark because at every 
cell division, this DNA methylation will be copied by DNMT1 onto a new daughter 
strand of DNA. A revised model of maintenance of DNA methylation proposes the 
participation of DNAMT3A and DNMT3B in addition to DNMT1 in this 
phenomenon[38]. According to this, the majority of DNA methylation during 
replication is copied by DNMT1 whereas DNMT3A and DNMT3B complete this 
process after replication. All the three methyltransferases are important for mammalian 
development and are required for maintaining viability of somatic[39] and cancer 
cells[40]. 
Although DNA methylation is a stable modification, its loss by either active or 
passive mechanisms has been observed in several biological contexts [Figure 6]. It 
happens in early development, in primordial germ cell development and during 
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differentiation[5]. In the passive demethylation, the DNA is replicated but fail to 
maintain the methylation in the absence of DNA methylation maintenance 
machinery[41]. Thus replication passively dilutes the DNA methylation. In contrast, 
active DNA demethylation is the enzymatic removal of the methyl group from 5mC or 
its modification. This enzymatic removal of the methyl group can happen in different 
ways via several chemical intermediates. The recent discovery of ten-eleven 
translocation (TET) family of oxidases has greatly advanced our understanding of the 
active DNA demethylation process[42]. These proteins catalyse oxidation of 5-
methylcytosine (5mC) to the intermediate modified base 5-hydroxymethylcytosine (5-
hmC)[43]. TET proteins further oxidize this intermediate to form 5-formylcytosine (5fC) 
and 5-carboxylcytosine (5caC)[44]. Active regulatory regions and actively transcribed 
genes show increased level of hydroxymethylation[45, 46] indicating its role in 
regulating enhancer activity in stem cells[47]. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6: Active and passive demethylation. 
Adapted from Schubeler, Nature 517, 321-326 (2015) 
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1.4.2  Functional role and genomic context 
 
DNA methylation has bimodal pattern with almost all CpG di-nucleotides being 
methylated except those located in CpG islands (CGIs).  These CpG islands tend to be 
protected from methylation or only dynamically methylated in germ cells[48]. The 
vastly studied inactivation by DNA methylation is X chromosome inactivation in 
mammals that involves DNA methylation of the CpG islands[49]. There are a couple of 
mechanisms through which DNA methylation suppresses gene expression. The 
primary mechanism involves binding of methylated CpG by proteins known as MeCP1 
and MeCP2 [50]. These proteins possess a transcriptional repression domain or 
alternatively, they can bring their own partner protein and condense the chromatin. The 
secondary mechanism, although not common, is that the methylated CpG itself will 
prevent transcription factor binding[51]. This secondary mechanism seems to be true for 
the transcription factors SP1[52], CTCF[53] and others. 
DNA methylation is also found at other regions of the genome and it has 
different functions according to different genomic context [Figure 7]. DNA methylation 
at promoters is mostly associated with transcriptional repression. However, 
“transcriptional repression driven by promoter methylation is inversely related to the 
distance of mCpGs from the TSS (transcription start site) and increases with promoter 
CpG content”[54]. CG rich promoters are mainly repressed by Polycomb proteins, 
which mark them with H3K27me3 (repressive mark)[55]. Nonetheless, instances of their 
repression via DNA methylation do exist. It is usually associated with long-term 
repression as evident in case of imprinted genes on inactive X chromosome[56, 57].  
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Figure 7: DNA methylation patterns. 
Portela & Esteller, Nature Biotechnology 28, 1057–1068 (2010) 
 
On the other hand, low CG content promoters are associated with dynamic DNA 
methylation[58]. It mostly confers tissue specificity by regulating the expression of 
genes required for particular lineage[59]. In contrast to promoters, gene bodies are CpG 
poor and mostly methylated. A recent genome wide study has shown that gene body 
methylation positively correlates with gene expression and is better determinant than 
promoter methylation[60]. DNA methylation is also notably found in inter-genic 
intervals and their repetitive elements[61] that are methylated to maintain genome 
integrity[62, 63]. In the absence of DNA methylation in these regions as shown by the 
cells lacking DNMT1, cells exhibit genomic instability[64, 65]. DNA methylation has a 
similar role at transposable elements of preventing them from autonomous 
	   24	  
transposition within genome (which is clearly mutagenic)[66]. Subsequently, 
methylation of these repeats can also prevent illegitimate recombination[67]. The 
silencing of the repeats forms the basis of the genome defence model proposed by Tim 
Bestor[68]. He proposed that the primary function of DNA methylation is to protect the 
genome from these transposable elements and this is certainly predominantly where 
DNA methylation is found. 
Cell differentiation is the process of forming specialized cells from pluripotent 
embryonic stem cells. This occurs by regulation of gene expression via selective 
activation of lineage specific genes and silencing of pluripotency genes. DNA 
methylation plays a key role in it by regulating the expression of important 
transcriptional factors OCT-4 and NANOG during early embryogenesis[69]. These 
factors selectively activate genes responsible for pluripotency while repressing genes 
required for cell differentiation. OCT-4 gene, necessary for pluripotency is expressed in 
embryonic stem cells but not in trophoblast stem cells. DNA methylation analysis 
revealed that the OCT-4 enhancer/promoter region is hypomethylated in ES cells but 
hypermethylated in TS cells[70]. In addition, de-novo DNA methyltransferase are also 
required for cellular differentiation by systematically regulating gene expression via 
promoter methylation. DNMTs show high expression in undifferentiated state while 
reduced expression in differentiated state[71]. Moreover, genes involved in 
pluripotency and differentiation undergo aberrant DNA methylation[72]. Extensive 
methylation changes were also found in regulatory regions outside of the core 
promoters during cellular differentiation[73]. The cytosine methylation also occurs in 
the non-CpG context at CHG and CHH sites (where H is A, C or T) in pluripotent cells 
where nearly one-quarter of all methylation occurs at non-CpG sites, especially in gene 
bodies[72] and in brain, where it is even more frequent than CpG methylation[74]. Non-
	   25	  
CpG methylation is lost with differentiation and is restored in induced pluripotent stem 
cells[72]. This suggests an important role of non-CpG methylation in the origin and 
maintenance of pluripotent state. In conclusion, the maintenance of DNA methylation 
pattern plays an important role in cellular development by modulating gene expression 
during entire lifetime of an organism. 
 
1.4.3  DNA methylation in cancer 
 
Cancer is not just a genetic disease, but rather it is genetic abnormalities partnered with 
epigenetic abnormalities. Epigenetic aberrations in cancer include locus-specific 
hypermethylation of CpG islands (CGIs) and genome-wide hypomethylation[75]. The 
genome in general is methylated in their repetitive elements through the intergenic 
regions and even in the introns of genes. In contrast, in cancer cell CpG islands are more 
likely (not all) to be methylated than in a normal cell[76–78]. The rest of the genome 
including the repetitive elements in these intergenic regions, and the introns are 
hypomethylated[79–81]. Hypermethylated CpG islands are found in the promoters of 
tumor suppressor genes thereby inactivating them. This acts as one of the hits of 
Knudson’s “two-hit” hypothesis[82]. This phenomenon occurs frequently in a number 
of different tumor type studied till date[83–85]. Genome-wide studies have also shown 
that the identity of hyper-methylated CGIs varies by tumor types/sub-type[86] and 
there is an increase in methylation level with cancer progression[87, 88].  
In addition to de-novo hypermethylation, cancer cells are also characterized by 
genome wide hypomethylation outside of CpG islands, which are generally methylated 
in normal cells. This decrease is mostly attributed to loss of methylation at repetitive 
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elements and retro-transposons. This results in illegitimate deletions, insertions or 
reciprocal translocations, and even duplication of chromosomes or loss of 
chromosomes; in general genomic instability. In ICF (Immunodeficiency, Centromere 
instability and Facial) syndrome, DNMT3B is mutated determining hypomethylation at 
centromeric repeats and leading to genomic instability[89]. Moreover, a number of 
studies have linked the absence of DNMT1 to genomic instability in cancer[64, 90]. 
Hypomethylation also occurs in other regions of the genome (apart from repeats) but it 
is less frequent. One such example is hypomethylation of CpG poor promoters 
associated with activation of oncogene RAS in gastric cancer[91]. 
DNA methylation in cancer has both hypomethylation genome-wide and 
hypermethylation of the tumor suppressor genes. But the driving role of DNA 
methylation is context dependent and different tumors have different dependencies on 
each of these particular aberrant methylation profiles. Some tumors are driven by tumor 
suppressor hypermethylation that enables them to continue to dividing rapidly[92]. 
While some types of cancers are driven by chromosomal instability due to 
hypomethylation[93]. Further several others change their dependencies throughout the 
lifespan of tumor [79, 94]. 
 
1.4.4  Technologies for measurement 
 
The experimental methodologies to profile DNA methylation have been revolutionized 
over the last decade. Profiling DNA methylation was previously restricted to one 
particular loci, while it can now be performed over entire genomes at single base 
resolution. These technologies vary according to sample throughput and genome 
coverage. The methods for profiling DNA methylation can broadly be classified into 
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three categories: I) digestion with methylation-sensitive restriction enzymes to 
fractionate methylated/un-methylated fragments[95], II) enrichment of methylated 
DNA fragments by methyl-cytosine binding proteins[96] or antibodies[97] and III) 
bisulfite treatment of DNA which converts un-methylated cytosines leaving methylated 
one unaffected[73]. Subsequently, the DNA methylation patterns information extracted 
through these methods is coupled with high throughput sequencing. 
 
Endonuclease digestion 
 
DNA methyltransferases as part of restriction/modification systems protect host DNA 
from cleavage by methylating bases in the recognition site of the restriction 
endonucleases. The methylation sensitivity of these restriction enzymes is used to 
elucidate read-out of DNA methylation from the patterns of their cutting. HpaII and 
SmaI are the most widely used restriction enzymes for DNA methylation studies[98]. 
The common methodology to discern differences in methylation is by detecting 
differences in the pattern of restriction fragments generated by digestion with a 
methylation-sensitive restriction enzyme separated by two-dimensional gel 
electrophoresis. Over the years different techniques have been developed that couple 
enzymatic methods to array-based analysis. The most optimized workflow in this 
category is comprehensive high-throughput arrays for relative methylation (CHARM) 
[99]. Further, restriction enzyme enrichment techniques are adapted to obtain 
methylation read-out by next-generation sequencing techniques. Methyl–seq is the most 
common method in which sequencing-by-synthesis of libraries constructed from size-
fractionated HpaII or MspI digests are compared with randomly sheared 
fragments[100]. Sequence-based analysis provides more genome coverage with less 
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input DNA, avoids hybridization artefacts and also allows allele-specific DNA 
methylation analysis.  
 
Affinity enrichment 
 
In affinity enrichment of methylated regions specific antibodies for 5mC or methyl-
binding proteins with affinity for methylated native genomic DNA are used for 
profiling DNA methylation.  In these methods methylated regions are enriched by 
immunoprecipitation of genomic DNA with an antibody specific for methylated 
cytosine, followed by hybridization to either a tiling array or microarray referred to as 
MeDIP[97, 101]. These techniques have been extensively used in studying the 
plant[102], mouse[59] and human methylomes[97, 99, 101]. In addition, other 
approaches uses antibody specific for higher affinity methyl-binding proteins (MBD) 
domains[103]. These affinity-enrichment methods are mostly combined with array 
hybridization in which the input DNA and enriched DNA are labelled with different 
fluorescent dyes. These methods allows for rapid and efficient assessment of genome-
wide DNA methylation. However, it does not yield information on individual CpG and 
requires adjustments for varying CpG density of different genomic regions. 
	  
Bisulphite conversion 
	  
Bisulphite conversion based methods revolutionized DNA methylation analysis. The 
denatured genomic DNA is treated with sodium bisulphite that chemically deaminates 
unmethylated cytosine residues while leaving methylated cytosines intact[104]. This 
chemical treatment of DNA converts the unmethylated Cs into Ts (by uracil) thereby 
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enabling DNA methylation detection at base-pair resolution[105]. Further, it is 
comprised of three different bases instead of four resulting in reduced sequence 
complexity.  This makes their adaption to array-hybridization techniques difficult and 
requires dedicated arrays based on the bisulphite-converted genome. Illumina adapted 
its 'BeadChip’ technology on Infinium I platform to generate a comprehensive genome 
wide profiling of human DNA methylation known as Illumina 27k methylation 
array[106, 107]. Infinium I has two beads per probe, one in the red channel and one in 
the green channel. The technology is further extended to 450k array that include an 
additional second assay type, Infinium II[108]. The 450k array contains 485,512 probes 
covering about 99% of RefSeq genes[108]. In addition to array- based methods, 
bisulphite-converted DNA is also combined with sequencing-based approaches. 
Reduced representation bisulfite sequencing (RRBS) is an efficient high-throughput 
technique to analyze the genome-wide methylation profiles on a single nucleotide 
level[109]. It combines restriction enzymes and bisulfite sequencing to enrich for high 
CpG content genomic regions. The size-fractionated DNA fragments are selected after 
BglII digestion or MspI digestion.  These fragments include the majority of promoters 
and CpG rich regions but do not target specific regions of interest in the genome.  The 
most comprehensive single-base-pair resolution DNA methylation analysis technique is 
whole-genome bisulphite sequencing. This has been utilized for profiling small 
eukaryotic genomes, such as A. thaliana[110], and for mammalian DNA[72].  
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1.4.5  Computational Tools for Epigenomics data analysis  
	  
To accelerate the research in the area of epigenetics, many international consortia have 
been formed during the last decade which explore its various aspects including DNA 
methylation, histone marks, chromatin accessibility and binding of regulatory 
proteins[111]. Integrative analysis of these epigenomics datasets provides holistic view 
on the interplay of various epigenomics component during biological processes and 
possible aberration in patterns in specific biological states. As a consequence, a 
multitude of data types, generated by different experimental methods is often 
combined in the same study. Numerous computational tools have been developed for 
the analysis of epigenomics data, typically focusing on specific analysis steps and data 
types[112, 113]. However, it remains difficult to understand the relative merits and 
performance of all the available approaches. Regarding DNA methylation, a 
comparative study has been performed on methods for identifying differentially 
methylated regions (DMRs) discussing the importance of experimental design along 
with confounding factors such as batch effects and cell type composition[114]. Many 
early WGBS studies used Fisher’s Exact test to identify DMRs[72]. However, recently 
beta-binomial is the most preferred statistical method implemented in several recent 
packages, such as BiSeq[115], DSS[116], RADMeth[117] and methylSig[118]. For other 
epigenomics data, Galaxy and Bioconductor resources presents a series of functionality 
critical for dealing with the complexity of their analysis [119, 120]. While the former is 
very intuitive to use, it is dependent on a limited set of embedded tools. On the other 
hand, Bioconductor currently offers more than 900 packages for the analysis of high-
throughput data, but it requires greater experience for the identification and use of the 
available resources. 
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1.5  Objectives 
	  
1.5.1  Development of Computational tools for the integrative analysis of 
epigenomics data 
 
Our understanding of epigenetic intricacies has considerably increased over the last 
decade owing to rapid development of genomic and proteomic technologies. The 
coupling of chromatin immuno-precipitation with next-generation sequencing (NGS) 
platforms (ChIP-Seq) has presented us with a comprehensive view of the epigenome. 
Earlier studies on the role of epigenetics in cancer were limited primarily to gene 
expression and DNA methylation, while recently more comprehensive epigenomics 
maps have shed light on the interplay between DNA methylation and histone 
modifications, and the subsequent impact on transcriptional programs[72, 74, 121]. 
Moreover, the results from International Cancer Genome Consortium about recurring 
somatic mutation in various cancer types have highlighted the presence of driver 
mutations associated to key epigenetic players[122]. These studies highlight the role of 
integrative analysis for deeper understanding of epigenomics regulatory mechanisms. 
Numerous computational tools have been developed for the analysis of 
epigenomics data but it requires greater experience for the identification and use of the 
available resources. Eventually, while experienced bioinformaticians are able to 
combine different tools and accommodate various input format requirements, simple 
and comprehensive tools for an integrative analysis of these various data types are 
missing. This leaves biologists generating high-throughput sequencing data to depend 
on help from other computational scientists. Hence, we intended to develop specific 
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methods that can efficiently handle whole genome base-resolution DNA methylation 
datasets and perform integrative analysis with other epigenomics components.  
To this purpose, we developed two companion packages for the integrative 
analysis of the most common epigenomics data types, providing easy access to what in 
our knowledge are the features most commonly requested by biologist, and facilitating 
the execution of routine tasks for bioinformaticians. Briefly, methylPipe supports the 
analysis of methyl- and hydroxymethyl-cytosines (mC and hmC, respectively) in both 
the CpG and non-CpG sequence contexts, derived from any methodology providing 
base- or low-resolution data. compEpiTools is a companion R package for the analysis, 
integration and simultaneous visualization of various epigenomics data types across 
multiple genomic regions in multiple samples. 
 
 
1.5.2  Studying epigenomics landscape of B-cell lymphoma 
 
Myc is a transcription factor and proto-oncogene that can activate or repress gene 
expression of target genes via dimerization with the partner protein Max and additional 
cofactors. Myc activation leads to induction of the tumor suppressor ARF, stabilization 
of p53, and subsequently induction of apoptosis[123]. Hence subverting the apoptotic 
response during tumor progression sets the selective pressure to mutate ARF or p53 in 
Myc-induced lymphoma[124]. However, considerable fraction of the lymphomas 
arising in Eµ-myc transgenic mice (a commonly used mouse model of Myc-induced B 
cell lymphoma) does not show mutations in those genes. This suggests that to allow the 
full development of Myc-induced lymphoma additional genes must be targeted. We 
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hypothesized that among these exist a set of tumor suppressor genes silenced via 
promoter CpG methylation that are positively selected during tumor progression. 
Hence, we applied the methods we developed (methylPipe & compEpiTools) for the 
identification of tumor suppressor genes regulated by DNA methylation in B-cell 
lymphoma.  
 
1.5.3  Epigenomics and genomics determinants of RNA methylation 
 
The methylation of RNA at the level of the N6 position of the adenosine (m6A), is 
emerging as an important area of investigation, thanks to the identification of enzymes 
critical for the establishment and regulation of this mark and the development of 
methodologies for its genome-wide investigation[125]. Commonly used methods are 
based on the immuno-precipitation with an antibody specific for m6A followed by 
high-throughput sequencing (MeRIP-seq), providing genome-wide low-resolution data 
about the patterning of this mark[126]. Based on this technique, a number of cell lines 
and tissues were profiled in mouse and human, identifying thousands of transcripts 
marked by m6A mostly in the 3’UTR, long internal exons and around the transcription 
start site (TSS), with a remarkable similarity between mouse and human[127]. The 
presence of this mark influences the splicing, translation, stability, localization and 
export of the transcripts, and the patterning of this mark can be dynamically established 
and removed, emphasizing the potential plasticity of this regulatory layer[127]. 
Recently, it has been found that m6A deposition is regulated by miRNA, and is critical 
for the processing of miRNA[128, 129]. Finally, RNA methylation has recently been 
shown to be relevant for the regulation of stem cells differentiation[130, 131]. 
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Most of the key actors so far associated with the establishment and regulation of 
m6A are enriched in nuclear speckles, where they have the potential to directly interact 
with nascent RNA in an environment rich in components of the splicing 
machinery[127]. Epigenetic marks, such as DNA methylation and histone post-
translational modifications, were also described to be involved in the regulation of the 
splicing process[132]. Nevertheless, there are currently no reports investigating on 
possible associations between RNA methylation and epigenomics or regulatory 
proteins such as transcription factors (TFs). In this study we explore this possibility, 
taking advantage of the fact that some of the cell lines used for studying m6A through 
MeRIP-seq experiments were extensively profiled through genomics and epigenomics 
approaches in independent studies. Specifically, we focus on the human embryonic 
stem cell (H1) and mouse embryonic fibroblast (MEFs). For the former, base-resolution 
bisulfite sequencing (for DNA methylation) data[72], a number of histone marks, and a 
number of transcriptional features (in ENCODE) are available, while for the latter low-
resolution MeDIP-seq (for DNA methylation) data are available[133]. 
 
 
  
	   35	  
Materials and Methods 
 
2. methylPipe 
methylPipe provides memory efficient analysis of base resolution DNA methylation 
data in both the CpG and non-CpG sequence context. It allows integration of DNA 
methylation data derived from any methodology providing base- or low-resolution 
data. 
 
2.1  Data Input and Processing 
	  
The input for methylPipe is base-resolution DNA methylation data that can be 
provided as tabular text files containing, for each profiled cytosine, the genomic 
positions and the number of reads with C or T (where the cytosine was protected or 
converted by the action of sodium bisulfite treatment[134], respectively). Alternatively, 
these data can be generated providing the path to SAM files of aligned reads such as, 
but not limited to, the alignment files obtained with the popular Bismark aligner[135]. 
Data are stored as Tabix-indexed compressed files[136] enabling compact 
representation and fast access to post-alignment processed DNA methylation data 
(BSprepare function). For example, the size of a compressed WGBS experiment for 
IMR90 and H1 human cell lines is 269MB and 380MB, respectively. Not only the limited 
size of this file results in a reduced disk space requirements (the size of the                                                                         
uncompressed flat files is 372MB and 554MB, respectively): these data can also be 
directly accessed from the disk, thanks to the Tabix indexing, further saving on the 
memory usage. Through this strategy methylPipe can easily accommodate data from 
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multiple WGBS experiments or any combination of WGBS and targeted base-resolution 
datasets. In addition to the methylPipe package, the complete set of mCs mapped in the 
IMR90 and H1 cell lines in the first human base-resolution DNA methylomes profiled 
by Lister and colleagues[72] are included in the ListerEtAlBSseq Bioconductor metadata 
package. The WGBS data available in this package were processed compressed and 
indexed with Tabix through methylPipe and can directly be accessed using the package 
functionalities. 
When post-alignment tabular DNA methylation data are processed in 
methylPipe through the BSprepare function, the confidence of calling a mC is 
determined for each C through a binomial test[72]. Briefly, sodium bisulfite treatment of 
DNA specifically converts unmethylated C to U (ultimately read as T) without affecting 
methylated C. For a given cytosine in the reference genome, the more sequencing reads 
have a C, the higher is the likelihood of that C being methylated. The binomial test is 
performed taking into account both the bisulfite conversion rate, which is typically 
calculated by sequencing of an unmethylated spike-in, and the sequencing error 
rate[72]. The resulting multiple-testing corrected p-values are stored on the disk in the 
Tabix compressed and indexed file, and are available in methylPipe through the BSdata 
class. This class has methods to easily access and filter the base-resolution data based on 
sequencing depth and statistical significance of the mC call. While using the binomial 
test to measure the confidence of a methylation event is straightforward in case of cell 
lines or very pure cell populations, its interpretation could be less direct in case 
contaminants or subpopulations with mixed epigenetic states are present in the sample. 
In those cases, the number of reads with C (#C, supporting the methylation call at a 
given cytosine), the number of reads with T (#T, not supporting the methylation call), 
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and the combined methylation level summary #C/(#C + #T) are available in the BSdata 
class and should be used for evaluating this heterogeneity. Further methods are being 
developed to resolve distinct epigenomes in mixed population[137, 138]. 
 
2.2  Descriptive Statistics of DNA methylation 
	  
methylPipe allows checking the basic stats about the methylation data such as range, 
mean and quantile distribution of methylation and assess sample similarity with 
correlation and clustering analysis. The methstats method computes pairwise correlation 
coefficients (Pearson) between the methylation profiles across all the samples in 
BSdataSet object. This function plots scatter plot and correlation coefficients, also 
outputs a correlation matrix [Figure 8]. In addition clustering of samples is performed 
based on the similarity of their methylation profiles and is displayed as a dendrogram 
[Figure 8]. 
These results can be used as quality controls on the data distribution of each 
individual sample and on the expected correlation structure between multiple samples: 
in an ideal experiment, replicates should be clustering close to each other, while 
samples from different conditions should be assigned to those specific groups. 
 
 
 
 
 
	   38	  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
In addition, methylPipe provides multiple methods for filtering the methylated 
cytosines based on any combination of the following: sequencing depth, methylation 
level and binomial p-value. This is available in the methods used to profile methylation 
patterns, identify differentially methylated regions or determine quality checks. 
 
 
 
Figure 8: Quality control metrics. 
Plot on the left pane shows the distribution of the methylation levels for each sample together with the 
pairwise scatter plot of these values comprehensive of p-values and R-values. Plot on the right pane 
reports the hierarchical clustering (Euclidean distance, complete linkage) of the samples based on their 
methylation levels, highlighting patterns and groups in the provided dataset. Distribution information 
and pair-wise correlation values are also returned at the command line for further processing of these 
results. 
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2.3  Profiling DNA methylation on genomic ranges 
	  
DNA methylation data are typically profiled over a set of regions of interest (ROIs) such 
as CpG Islands or gene promoters. A class inheriting from the Bioconductor 
SummarizedExperiment class was defined for this task (GEcollection class) and has data 
slots specific for the absolute and relative density of DNA methylation events, which 
can be populated with the profileDNAmetBin method. The absolute methylation level of 
a genomic region (or bins thereof) is determined as the number of mCs per base-pair, 
while the relative methylation level is determined as the proportion of mCs over the 
total number of potential methylation sites in that region. While the methylPipe 
GEcollection class is designed to profile DNA methylation in a set of genomic regions for 
a single sample, the class GElist can be conveniently used to collect the same 
information for a number of samples and pass it to other methylPipe or compEpiTools 
methods.  
Particular attention was dedicated to the strategy used for incorporating base-
resolution information about unmethylated and uncovered (unsequenced) cytosines. 
While unmethylated Cs are the vast majority of the cytosines in all profiled 
genomes[139], the amount of uncovered Cs depends on the experimental technique 
adopted. Different techniques are available for the acquisition of base-resolution DNA 
methylation profiles. These can target the whole genome (WGBS) or only a subset of it, 
focusing on CpG-rich (Reduced Representation of Bisulfite Sequencing, RRBS[73]) or 
custom regions (such as the approach based on padlock probes[140]). In WGBS, most of 
the Cs are profiled, thus there is a limited number of uncovered Cs, and a majority of 
unmethylated Cs. On the other hand, RRBS or padlock experiments only cover a limited 
portion of the genome, resulting in data where few unmethylated Cs are vastly 
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outnumbered by a large majority of uncovered Cs. As a trade-off between these 
extremes, we decided to include in the BSdata class only the cytosines where at least 
one sequencing read has a C, thus building support on the methylation call. In addition, 
we provide a function to generate a GRanges including all the unmapped regions (with 
no sequence data) based on a BAM file, as most of the uncovered cytosines tend to 
occur in a limited number of refractory regions in WGBS experiments or in a relatively 
small number of regions complementary to the RRBS or padlock targeted regions. In 
this way, (i) considering Cs with #C >0 and (ii) having the list of the regions containing 
uncovered Cs, we can exactly recover the methylation status for each C in the genome 
as methylated (at a significant or not significant level), unmethylated or unmapped. 
Importantly, this piece of information is critical for the identification of the differentially 
methylated regions by methylPipe. Eventually, this results in a compression of WGBS 
experiments in relatively small files, while maintaining the ability of efficiently 
accommodating and integrating experiments with any level of genome targeting. 
 
2.4  Identification of differentially methylated regions 
	  
The findDMR function uses the Wilcoxon or Kruskal-Wallis paired non-parametric tests 
for the identification of differentially methylated regions (DMRs) between two groups 
of samples or between multiple samples, respectively, by comparing the mC 
methylation levels. Briefly, the algorithm adopts a dynamic sliding window approach 
that identifies regions suitable for testing depending on mC density and relative 
distance, and possibly excluding regions with no, or negligible, variation between 
groups. More in detail: 
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i. A cytosine identified as methylated by the binomial test, having a minimum 
sequencing depth and a minimum methylation difference among the samples to 
compare (all these cutoffs are user-defined), is identified as the seed. 
ii. Downstream Cs, satisfying the same criteria, within a maximum distance (D) from 
the seed is then considered. A minimum number of Cs (data points) is required 
within that window, while allowing a maximum number of missing data 
(unmapped Cs). 
iii. The methylation level of the considered Cs is then compared between the samples 
using the statistical tests described above. 
iv. The first mC call downstream of the position of the first seed C incremented of D/2 
bp is considered as the seed of the next window and the process repeats from (i). 
Alternatively, the findDMR function can utilize average methylation levels in 
discrete genomic regions. This could be useful in case of non-CpG methylation events, 
which are more unevenly distributed in the genome compared to mCpGs. Importantly, 
it is possible to upload GRanges with a list of Cs associated to known SNPs, which 
could confound the DMR analysis and that are consequently discarded. Moreover, 
when comparing differentiated to pluripotent cells it is suggested to include a GRanges 
object defining the partially methylated domains (findPMDs), which are large regions of 
partial methylation typical of differentiated cells that could cover up to 30% of their 
genome[72]. These regions are, by definition, differentially methylated when compared 
to pluripotent cells, and should be skipped in the DMR analysis presented here, which 
is targeted to smaller differential regions. Eventually, the consolidateDMRs function 
applies multiple testing correction to p-values, and significant genomic regions that are 
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close enough by an user-adjustable threshold are merged (their corresponding p-values 
are combined using Fisher’s method).  
The findDMR method was proven useful for the identification of DMRs in a number 
of studies[141, 121], resulting in the identification of genomic regions confirmed by 
other independent studies[140, 142]. In addition, the method was successfully adopted 
for the simultaneous analysis of hundreds of A. thaliana WGBS methylomes[143, 144], 
which are characterized by mosaic DNA methylation patterns[110]. Thus, methylPipe 
has been shown to be effective not only in the analysis of very large datasets, but also in 
managing DNA methylomes of various species, and in particular DNA methylomes 
with peculiar mC patterning compared to mammals. 
Recently, an additional type of cytosine methylation was discovered, the 5-hydroxy-
methylcytosine (hmC), which was proven to be a critical intermediary in active de-
methylation pathways[145]. Bisulfite sequencing experiments do not distinguish hmC 
from mC. Specific experimental methods for the identification of this mark at the base-
resolution were developed, and MLML is a popular computational method for a first 
analysis of these data[146]. methylPipe includes the process.hmc function to parse the 
MLML output and create a BSdata object specific for the hmCs data, which can then be 
combined with any other kind of DNA methylation data using the package 
functionalities. 
2.5  Data integration and Visualization 
	  
A wide array of alternative methods providing low-resolution DNA methylation 
estimates is available, including MeDIP- or MBD-seq; these assays are based on the 
binding of mCs by a specific antibody or methyl-binding protein, respectively. 
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Computational methods are available to convert these low-resolution data into high-
resolution estimates[147–149]. These high-resolution data can be subsequently imported 
in methylPipe as if they were native high-resolution bisulfite data. Alternatively, low-
resolution data describing the methylation of genomic regions can be incorporated in 
methylPipe at the level of GEcollection and GElist objects, which were designed to 
summarize mC density in genomic regions. 
Finally, the plotMeth method was developed to visualize DNA methylation base-
resolution data, as well as their summary over genomic regions (or low-resolution DNA 
methylation data) along with gene models and other omics data or annotation tracks. 
This method, which allows a genome-browser like visualization of a specific genomic 
region, takes advantage of the Gviz Bioconductor library [Figure 9]. 
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2.6  Computational performance of methylPipe 
	  
The computational performance of methylPipe was tested on whole genome bisulfite 
sequencing data from Lister et al 2009 (Table 1).  
a) Data Processing: TABIX compression, indexing and computation of binomial tests, 
which are the steps necessary to create a new BSdata object in methylPipe, took 30 
minutes with 1 core (max 4GB RAM peak usage) for the human H1 stem cells[72].  
b) Profiling methylation data: After the data processing step, access to the data is fast: 
with one core, it can profile 100 human promoters in a sample in about 50 seconds 
(max 1GB RAM peak usage).  
c) DMRs identification (pairwise): DMRs identification between 2 WGBS samples took 
20 minutes with 1 core on chromosome 1 (max 4GB RAM peak usage), and 45 
minutes with 10 cores for a genome-wide analysis (max 28GB RAM peak usage on a 
cluster).  
d) DMRs identification (multi-sample): Finally, the most computationally intense task, 
i.e. the identification of DMRs among 8 WGBS methylomes[141], on chromosome 1 
Figure 9: Base-resolution DNA methylation patterns displayed for a specific gene 
locus.  
In this plot, DNA methylation is profiled for H1 and IMR90 samples in the identified 
DMRs. The “red” track represents the DMRs. The base resolution data is represented in 
H1_BS and IMR_BS tracks with methylation level ranging from 0-1. For each genomic 
region the absolute methylation density (mC/bp), the density of possible methylation sites 
(C/bp) and the relative methylation level (mC/C) is determined. The relative methylation of 
the DMRs in H1 and IMR90 are displayed in “green” track. This information is overlaid 
with genomic annotation using plotMeth. These tracks are visualized for the OCT4 locus, a 
key developmental gene, whose promoter is well known to be hypo-methylated in pluripotent 
cells, such as H1. 
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took 40 minutes with a single core (max 4.9GB RAM peak usage), proving to be 
manageable even on a laptop computer. Parallelization is implemented in the 
package, and it automatically adjusts to the available number of cores and RAM. 
The same DMR analysis of 8 WGBS methylomes could in fact be completed in a 
similar time on a cluster by assigning 10 cores. 
Table 1: Computational performance of methylPipe 
Functions Time Taken Memory Required 
Data Processing1 30 mins 4 GB 
Profiling promoters (100) 50 secs 1 GB 
Chromosome-wise DMRs 
Identification 
(pairwise)[72] 
20 mins 4 GB 
Whole genome DMRs 
Identification (pairwise) 
45 mins 28GB (10 cores) 
Chromosome-wise DMRs 
Identification 
(multiple)[141] 
40 mins 5 GB 
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2.7  Comparison with other tools 
	  
We compared the differentially methylated regions (DMRs) identified by methylPipe with 
other published tools using WGBS dataset (Lister el al, 2009). To assess the DMRs identified 
by methylPipe, we compared them to those identified by methylKit[150], methylSig[118], 
RADMeth[117], methPipe[151] and DSS[116] in terms of number of regions, overlap, and 
annotation. Some important issues complicating this comparison are following:  
i. Some tools identify differentially methylated sites (DMCs) 
ii. Some tools would not work with genome-wide WGBS for the DMR identification 
iii. The difference in method of DMR identification 
Keeping the above issues in mind, we tried to reach an approximate comparative estimation 
of DMRs by setting threshold on methylation difference (> 30%) and statistical significance (q-
val< 0.05). We compared all the tools able to perform DMR (DMC) identification on genome-
wide WGBS together with those only able to work with a very limited subset of the data. To 
this purpose, we only considered H1 vs. IMR90 methylation data for chr1. The following 
heatmap [Figure 10] (generated by overlapOfGRanges method of compEpiTools) reports the 
number and % overlap between the DMRs (DMCs) identified from the various considered 
methods: 
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Figure 10: Heatmap of percentage overlap of DMRs/DMCs identified by various 
methods. 
The figure displays the percentage overlap of DMRs/DMCs identified by various software 
tools between H1 and IMR90 cell line. Each box in the heatmap represents the pairwise 
percentage overlap of the regions identified as DMRs by both packages. 
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methylPipe, methylKit and methylSig shows reasonable percentage overlap of the identified 
DMRs regions. However, RADMeth, methPipe and DSS provide very discordant results. 
RADMeth identified 1635k individual DMCs, methPipe identified 609k DMCs whereas DSS 
only identified 261 individual DMCs. The overlap is calculated in respect to the method 
reported on the vertical axis (for example the first heatmap row is about the percentage of 
methylPipe detected regions confirmed by the other methods). While all this does not 
reassures about the bona-fide DMR identification it can be noticed that the first three methods 
have a good agreement. For example 57% and 79% of the methylPipe DMRs are confirmed by 
methylKit and methylSig, respectively, while methylKit basically provides a subset of the 
regions identified by methylSig. The comparison with the other three tools (RADMeth, 
methPipe and DSS) is greatly complicated by the very discordant number of sites identified. 
However, methylPipe shows good overlap with all the tools except DSS. All the identified 
DMRs/DMCs are further annotated (using GRannotateSimple method of compEpiTools) 
according to their genomic location [Figure 11]. As expected, methylPipe, methylKit and 
methylSig show similar annotation patterns of identified DMRs where RADMeth, methPipe 
and DSS show discordant genomic annotation patterns. 
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Figure 11: Genomic annotation of identified DMRs/DMCs. 
The figure displays the percentage genomic annotation of DMRs/DMCs identified by various software 
tools between H1 and IMR90 cell line based on overlap with promoters, intergenic and intragenic regions 
derived from UCSC based annotation 
.  
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3. compEpiTools 
	  
compEpiTools functionalities can be grouped in three main categories: (i) computing 
various read counts metrics in genomic regions, (ii) performing functional/genomic 
annotation, and (iii) integrated visualization of heterogeneous data-types. 
 
3.1  Computing read counts metrics 
	  
compEpiTools facilitates several common operations associated with the quantification 
of the sequencing signal in a set of genomic regions. The base-level or overall count of 
reads within a set of regions can be determined based on BAM files, using the 
GRbaseCoverage and GRcoverage methods, respectively. Resulting counts can be 
normalized by library size and/or region length. In addition, specifically for ChIP-seq 
experiments, the peak summit position and the overall region enrichment given a 
matched input sample can be determined, through the GRcoverageSummit and 
GRenrichment method, respectively. Regarding RNA Polymerase II (RNAPII) ChIP-seq 
experiments, the stallingIndex and plotStallingIndex functions are available to compute 
and visualize the cumulative distribution of the stalling index (SI), thus estimating the 
degree of RNA Polymerase stalling[152]. The SI is defined as the ratio of the RNAPII 
signal in the promoter and genebody region. When comparing different samples, the SI 
could increase significantly because of either an increase at the level of RNAPII in the 
promoter or a decrease of in the genebody, or because of differential dynamics of 
RNAPII in these two regions. For this reason, to better dissect the dynamics of 
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differential SI, the cumulative SI distribution is conveniently integrated with the 
analysis of promoters and genebody RNAPII read densities. 
 
3.2  Genomic Annotation 
	  
To ascertain the biological significance of a set of ROIs (ChIP-seq peaks, DMRs etc.), it is 
important to consider them in their genomic context. compEpiTools allows an effortless, 
rich and fast annotation of genomic regions based on Bioconductor standard annotation 
libraries derived from the UCSC genome database, using the GRannotate method 
[Figure 12]. Specifically, for each ROI, the distance from the nearest transcription start 
site and its location are determined. The region location is also annotated based on the 
overlap with promoters, intragenic and intergenic genomic regions, and the 
corresponding transcript and gene id(s) and symbol(s) are reported. The resulting 
GRanges conveniently embed the annotation for all the isoforms that might occur in 
correspondence of a given ROI. Notably, the user is provided the flexibility to supply 
additional sources of annotation, which could results from other omics analyses. These 
might also be any list of ROIs taken from the literature, or obtained within R using the 
ucscTableQuery function from the rtracklayer package to access UCSC Tables (e.g. the 
list of CpG Islands). 
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Figure 12: Genomic annotation output for the region of interest. 
The method GRannotate based on a GRanges and a TxDb, returns the GRanges with a series of 
annotations. The program annotates the genomic regions of interest based on Bioconductor standard 
annotation libraries derived from the UCSC genome database. For each ROI, the distance from the 
nearest transcription start site and its location are determined. The location is further annotated 
based on the overlap with promoters, intragenic and intergenic genomic regions, and the 
corresponding transcript and gene id(s) and symbol(s) are reported. 
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3.3  Functional Annotation 
	  
Genomic regions can also be annotated in a number of epigenomic relevant states. The 
enhancers method can be used to identify enhancers based on promoter-distal H3K4me1 
(indicative of enhancers that could be either active or poised) or H3K27ac (indicative of 
active enhancers) ChIP-seq peaks, possibly excluding CpG Islands regions [Figure 13]. 
Using the matchEnhancers method, enhancers can conveniently be matched to the most 
proximal genes, and possibly stratified based on the association to transcription factor 
(TF) binding events to study the TF-dependent activity of enhancer regions and 
putative target regions. 
	  
Figure 13: Enhancers identification. 
Enhancers are defined as distal H3K4me1 peaks not overlapping with CGI, to avoid un-annotated 
transcriptional units. Alternatively H3K27ac peaks could be used to identify active enhancers. 
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Particularly relevant for DNA methylation is the concept of promoter CpG-
content, which is critical for the epigenetic control on the downstream gene expression: 
variation in the absolute or relative methylation at the level of intermediate or high-
CpG density promoters was proven to be associated to differential expression of the 
downstream gene, compared to low CpG content promoters[153]. The promoter CpG 
context can be determined with compEpiTools through a sliding window scoring 
approach proposed by[101], implemented in the getPromoterClass function [Figure 14]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 14: Promoter class by CG content. 
getPromoterClass can be used to classify promoters according to their CpG content. In the plot, 
the promoter CpG content is determined and promoters are classified into low-, intermediate- and 
high-CpG content. Then, relative DNA methylation (mC/C) is profiled for promoters in the three 
classes. As can be expected, highCG content promoters have lower methylation level whereas; 
lowCG and intCG promoters have considerably higher relative methylation around the TSS. 
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Long non-coding RNAs (lncRNAs) can be identified in compEpiTools using the 
findLncRNA function based on their epigenetic signatures. Briefly, H3K4me3 peaks 
distal from promoters and associated with a lower H3K4me1 reads density (thus 
avoiding enhancer regions), are identified as seed for the identification of potential 
lncRNA promoters. Evidence for RNA transcription in the regions downstream and 
upstream these H3K4me3 peaks are evaluated by computing the read density of RNA-
seq, H3K79me2 and/or RNAPII. Random genomic regions of the same size, not 
overlapping with promoters, are used as a background to determine the random 
expected density of these marks of transcriptional activity. Regions with a signal for 
these marks greater than the 95th percentile of the background are then selected as 
putative regions expressing lncRNAs. 
Finally, a convenient wrapper (topGOres) is provided to perform GeneOntology 
(GO) enrichment analysis on a set of Entrez gene ids (query) based on the topGO 
Bioconductor package [Figure 15]. A common problem in the analysis of GO 
enrichments that complicates the interpretation of the results is the redundancy 
between enriched GO terms that are very close in the considered ontology. For this 
purpose, compEpiTools provides the simplifyGOterms function for pruning poorly 
informative and redundant enriched terms. The rationale behind this pruning is that 
often parent and a child enriched-terms point to very similar GO terms, associated to a 
very similar set of genes. Iteratively, for each enriched term T, the parent of T is 
searched within the set of enriched terms, based on the specified ontology. If both a 
parent and a child terms were identified as enriched and if they match to a set of genes 
overlapping more than a user-adjustable threshold within the query, the parent term is 
discarded in favor of the more specific child term. 
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Figure 15: GeneOntology annotation plot. 
topGOres is used to identify significantly enriched GeneOntology terms. The plot (output of 
topGOres) displays the top ranking terms with number of genes and associated p-value (-log10 
(p-value)). 
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3.4  Data integration and visualization 
	  
The integration of heterogeneous data types is a challenging task, and explorative 
analyses based on the generation of heatmaps are frequently used to highlight patterns 
in combined datasets. In our experience, the creation of such heatmaps requires an 
extensive number of processing steps, especially when applied to datasets composed of 
heterogeneous data types and annotation tracks, discouraging the repeated use of these 
tools. Rather, heatmaps are typically iteratively generated until a satisfactory 
combination of data tracks, clustering and normalization settings is identified. A 
powerful and efficient visualization system based on heatmaps is provided in 
compEpiTools, based on the heatmapData and heatmapPlot functions. Heatmap rows 
represent ROIs and columns represent data tracks. Every track can be assigned to any of 
the supported data types: GRanges, GRanges metadata, BAM files, and GElist and 
GEcollection objects generated by methylPipe. Thus, any combination of base-
resolution or low-resolution DNA methylation data, histone marks, TF binding, RNA-
seq expression and genomic annotations, including gene models, is accommodated. 
Quantile or thresholding-based normalization methods can be activated independently 
for each track, to emphasize patterns in the combined dataset and adjust the signal 
range of the track (for example to exclude outliers or underweight data tracks that are 
overall poorly scoring in the ROIs). Clustering of rows can be activated, including data 
from all or selected tracks. Dividing each ROI in a user-defined number of uniformly 
sized bins can control the resolution of the displayed data. Importantly, each track can 
be supplied with significance scores, which can be conveniently used to progressively 
dim the color of low-scoring (less significant) hits, while maintaining full brightness for 
the significant ones. The data matrix underlying the heatmap is returned together with 
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the dendrogram structure, allowing further analysis of the clusters of interest [Figure 
16]. 
 In the following plot, the regions of interest (plotted regions) is determined 10 kb 
upstream and downstream of each of the DMRs identified as hypo-methylated in H1 
compared to IMR90 on chromosome 6 (methylation difference greater than 25 percent). 
For these regions (ROIs), the heatmapData function is used to integrate data from various 
data types. The relative density of DNA methylation is computed using 
profileDNAmetBin function of methylPipe. For H3K4me1 and H3K4me3 data tracks (in 
both H1 and IMR90 samples) are provided as GRanges containing pre-determined 
ChIP-seq peaks (while they could contain any kind of genomic regions). These tracks 
are represented in the heatmap, as presence or absence of a ChIP-seq peak for each ROI 
(or bins thereof). For H3K27me3 and H3k36me3 data tracks the path to the aligned 
reads stored in BAM files (limited to chr6) are provided. The heatmapData function 
consequently computes the reads density (coverage) for these BAM files in the ROIs. 
The reads density is further normalized by library size. Finally, the RNA-seq data 
tracks, the pre-computed reads density is provided for both the H1 and IMR90. The 
resolution of the data to be displayed for each track is defined based on the number of 
bins (nbins) that each ROI is uniformly divided into (20 in this example). 
 
The list resulting from the heatmapData function is passed to heatmapPlot to 
display the heatmap. This is convenient in case one would repeat this step testing 
several plotting and normalization settings, saving the time needed to determine the 
raw data underlying the heatmap. When calling heatmapPlot the data can be normalized 
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independently for each track based on a specific signal percentile (which is set as the 
maximum saturation value and displayed as 1, corresponding to full red in this 
example), or based on a specific arbitrarily chosen threshold. In this case a hybrid 
approach is used. Several tracks for the same data type (for example histone reads 
density) are temporarily combined and their overall 85th percentile is set as the 
maximum value. The gene annotation information for the forward and reverse strand 
can be automatically extracted from a TranscriptDb object and overlaid in the heatmap, 
reporting exons in red and intron in pink. This offers the possibility of adding a 
commonly desired annotation track, using a custom graphic representation to highlight 
introns and exons. The clustering of rows can be activated specifying the index of the 
tracks to be used for clustering; in this case all of them are used including gene 
annotation tracks. This option could be useful to direct the clustering to use only a 
subset of the data or annotation tracks, increasing the flexibility and allowing 
emphasizing various patterns in the data. 
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Figure 16: The integrative heatmap generated by heatmapData and heatmapPlot functions. 
Heatmaps can easily be obtained incorporating any mixture of data and annotation tracks. Heatmap rows 
represent ROIs, while columns represent tracks profiled over those ROIs (or bins thereof). Data and annotation 
tracks might contain either quantitative (e.g. normalized reads counts) or categorical (e.g. presence/absence of a 
ChIP-seq peak) data. If available, the significance of associated data can be incorporated affecting color brightness. 
In this example, generated as described in detail in the supplemental material, NIH Roadmap DNA methylation 
data where visualized together with ENCODE histone marks for a set of differentially methylated regions. ROIs 
were clustered based on the data available in all the displayed tracks including gene models annotations. The 
schema on the top of the figure depicts the workflow leading to the heatmap. A set of standard Bioconductor 
objects, listed in red, is the input for the heatmapData and heatmapPlot compEpiTools functions. The underlined 
text points to the key analysis steps automatically performed internally to the functions generating the heatmap, 
calling routines available in the same packages. 
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3.5  Computational performance and comparison with other tools 
	  
Most of the functionalities offered by compEpiTools can be run on the order of minutes 
or less. For example, profiling the normalized number of reads from a GRanges of 
40.000 ROIs and a typical BAM ChIP-seq file takes less than 40 seconds. Dividing each 
region in a number of bins does not require much additional time, because the binning 
is performed after the initial count, which is the most time consuming step. Building 
heatmaps with a dozen of tracks is typically performed in a few minutes, mostly 
depending on the number of ROIs to be clustered. To achieve maximum efficiency, 
optimized clustering routines, as implemented in the fastcluster R package, are 
adopted[154]. The only tool which to our knowledge is comparable in functionality 
with compEpiTools is the Bioconductor RepiTools package[155]. While RepiTools 
provides a useful set of tools for the integrative analysis of epigenomics data, mostly 
focused on statistical testing, integration with gene expression data and visualization, it 
is tailored to enrichment-based epigenomics data only, and it is unable to provide most 
of the compEpiTools functionalities listed in Table 2. 
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Table 2: Comparison of methylPipe and compEpiTools features with functionalities offered 
by other similar tools. The first column lists the key features offered by methylPipe and 
compEpiTools. Column headers report the tool name and reference. A “+” sign indicates that 
the feature is provided by a given tool, while a “–“ sign indicates that it is not available. The 
“Pairwise DMR analysis” row includes in parenthesis the time (in minutes or days) needed for a 
complete WGBS differential analysis between two samples; NA is reported if this analysis is not 
supported for WGBS data. (a) WBSA is an online web-service imposing a limitation or 2GB for 
the upload of fastq files, which is clearly insufficient for the analysis of a WGBS dataset; the 
software can be installed locally although this requires significant effort (requiring Perl, R, 
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MySQL, Java and C compiler) and it is only available for Linux; the analysis of the H1 and 
IMR90 WGBS was reported by the Authors to be completed in one week.  
 
Table 2 provides a comparison of the features offered by methylPipe and 
compEpiTools with those offered by other computational tools able to analyze 
epigenomics data. Most of the tools available for the analysis of these data are 
implemented as R packages, focusing only on the analysis of DNA methylation data. 
Currently, 38 packages are available in Bioconductor associated with the DNA 
methylation assay domain. The large majority of these packages were developed for the 
analysis of data generated with the 450K Illumina platform, which is able to profile only 
about 1% of the cytosines that are typically found in a complete human DNA 
methylome. Only four of these packages (BiSeq, M3D, bsseq and DSS) are potentially 
able to manage WGBS data. These packages provide a very limited subset of the 
functionalities offered by the methylPipe / compEpiTools packages, most of these tools 
were developed and tested for the identification of DMRs on RRBS data (Table 2), and 
claim to be able to analyze WGBS data. We tested whether they could perform three 
specific tasks that we consider necessary in the analysis of WGBS data:  
I. Uploading a single WGBS dataset and profiling a set of ROIs,  
II. Identifying DMRs between 2 conditions,  
III. Identifying DMRs between multiple conditions.  
BiSeq[115] and M3D[156] are designed to upload the entire dataset into memory, and 
we failed with both in uploading an entire WGBS dataset even when 80GB of memory 
was provided (we could only upload and work with data for chromosome 1). 
Consequently, we were unable to perform any of the three proposed testing operations. 
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Regarding the remaining programs, bsseq[157] only provides a smoothing-based 
method to identify DMRs, without offering additional functionalities, and DSS[116] is 
not specific for DNA methylation data. Neither of these tools delivered satisfactory 
results: DSS completed the DMR identification in a 2-group comparison in about 3 days, 
while after the same amount of time bsseq returned an error. In addition to these 
Bioconductor packages, few additional stand-alone tools or web-services are available 
to manage base-resolution DNA methylation data. Among these, only methPipe[151] 
and RADMeth[117], both developed by the Smith Lab, can analyze WGBS datasets and 
perform DMR analyses. The time needed by these tools for the identification of DMRs 
(36 and 90 minutes, using 1 and 10 cores respectively) is similar or slightly higher than 
methylPipe (45 minutes using 10 cores) (Table 2). To our knowledge, the examined 
tools do not provide an extensive set of supplemental functionalities beyond to those 
listed in the Table 2. In this regard, methPipe is the only exception, providing additional 
routines that are complimentary to those offered by methylPipe. In summary, only 
methPipe and RADMeth were able to efficiently complete the proposed tasks with 
standard resources. Importantly, neither these tools nor the other software packages, 
limited on the analysis of targeted DNA methylation data, could match the complete set 
of functionalities offered by methylPipe and compEpiTools (Table 2). 
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Results 
	  
4. Epigenomics landscape of B-cell lymphoma 
	  
This study is being carried out in Dr. Bruno Amati lab where Dr. Alessandra Majorana 
(post-doc) has designed the experiment, prepared the RRBS library and is further 
carrying out the experimental validation of the computational results. We have 
analyzed the RRBS methylation data, developed methodology for the integrative 
analysis of DNA methylation data with ChIP-seq and RNA-seq data and finally 
identified a list of putative tumor suppressor genes for experimental validation. 
 
4.1  Experimental Methods 
 
 
To identify genes silenced by CpG methylation we collected samples from Eu-myc mice 
in tumor stages (four biological replicates) and B-cells from normal mice (three 
biological replicates) that we used as control and subjected them to genome wide 
methylation analysis through Illumina sequencing. We used Reduced Representation 
Bisulfite Sequencing (RRBS) a bisulfite-based protocol that enriches CG-rich regions of 
the genome, thereby reducing the amount of sequencing required while capturing the 
majority of promoters[160]. The advantage of this method is that it provides single-
nucleotide resolution with high sensitivity and limited cost. 
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4.2  Data processing 
	  
We developed the computational pipeline for the analysis of RRBS data. Firstly, we 
performed preprocessing of bisulfite reads by removing bad sequencing and low 
quality reads. The processed reads were thereafter aligned to the reference genome 
mm9 using the Bismark aligner (v0.5.4). The DNA methylation information in terms of 
percentage methylation with coverage at each cytosine is then extracted from SAM file 
generated from Bismark. Since a high enough read coverage would increase the power 
of the statistical tests, the bases with low read coverage (< 5) were discarded from 
further analysis. To remove PCR bias, the bases that have more than 99.9th percentile of 
coverage in each sample were also discarded. 
 
4.3  Coverage Statistics 
 
To assess the empirical genome coverage of the method, we calculated the number of 
reads for each of the following regions: I) CpG Islands II) Gene promoters (defined as 
±1kb of TSS). The results show [Figure 17] that RRBS covered most of the CpG islands 
and promoters. The coverage is consistent across all the samples reassuring on the lack 
of coverage biases in any of the samples that could have affected down-stream analyses. 
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4.4  Identification of Differentially methylated Regions (DMRs) 
	  
DMRs were identified by computing the number of methylated versus un-methylated 
CpGs and tested for statistically significant differences between two samples using 
Figure 17: Coverage statistics. 
The figure above shows number of individual CpG methylation measurements for the CpG Islands (top) 
and promoters (bottom) for control sample (WT43245) and tumor sample (LY27805) and. Promoter 
regions were calculated based on Ensembl gene annotations, such that the region starts 1 kb upstream of 
the annotated transcription start site (TSS) and extends to 2 kb downstream of the TSS. CpG islands 
information were obtained from the UCSC browser. 
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Fisher’s exact test. The replicates within the normal group are pooled together and 
compared with tumor samples. The complete tiling of the genome was performed for 
genome-wide DMR detection. The genome was tiled with windows 100bp length and 
100bp step-size. This generated a list of DMRs for each comparison with percentage 
methylation and p-value. Following the differential methylation test and calculation of 
P-values, sliding linear model (SLIM) method was used to correct P-values to q-
values[161], which corrects for the problem of multiple hypothesis testing. Thereafter, 
the hyper-methylated and hypo-methylated regions that have q-value<0.05 and percent 
methylation difference larger than 20% were selected. In total, 26585 hyper-methylated 
DMRs were selected from four tumor samples compared to control. These regions were 
put into genomic context by annotating them according to their genomic location. 
 
4.5  Annotation of DMRs 
 
To ascertain the biological significance of each differential methylation events, it was 
put into its genomic context for subsequent analysis. Thus, each list of DMRs was 
annotated according to their location with regard to CpG islands, proximity to the 
nearest transcription start site (TSS) and gene components, e.g. intron and exons. The 
annotation was performed using GRannotate function of compEpiTools. 
 
4.6  Associating DNA methylation with RNA-seq Information 
 
 
To discern the tumor suppressor genes that are silenced through cytosine methylation 
within CpG elements of their promoters, it was important to associate gene expression 
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information with the differential methylated regions. Therefore, all the DMRs within 
the promoter region (-1kb upstream and +2kb downstream of TSS) of each gene that 
were simultaneously hyper-methylated were combined. Differential methylation 
percentage is computed for each gene by computing average of all methylation 
differences of the combined regions. A combined q-value of these regions is computed 
by Fisher method. The gene expression information (RNA-seq) was mapped to the 
differential methylation information for each gene. Only the genes hypermethylated by 
more than 20% and displaying change in gene expression greater than two fold were 
considered for the analysis.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 18: Associating DNA methylation with RNA-seq information. 
The figure above represents the log2 fold changes of gene expression and DNA methylation for tumor 
sample v/s control samples. Each point on the plot represents a gene with red ones are the genes, which 
are statistically significantly differentially expressed (q-value < 0.05) with hypermethylated promoter 
(q-value < 0.05). 
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We did not observe strong overlap between alteration in DNA methylation and 
expression differences in tumor [Figure 18]. This observation can be reconciled with the 
hypothesis that DNA methylation plays an important role in transcriptional silencing of 
tumor suppressor genes but it affects only a moderate number of genes, rather than a 
large and unspecific set of genes. It may be reasoned that most genes most of the time 
are not actively regulated by DNA methylation. Given the relatively small number of 
genes with overlapping DNA methylation and gene expression changes, we reasoned 
that genes exhibiting consistently negative association between these two properties 
might constitute potential tumor suppressor gene candidates [Figure 19]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 19: UCSC view of hypermethylated gene promoter. 
The figure displays tracks of base resolution DNA methylation level for control and tumor samples. 
Timp3 gene is hypermethylated and down-regulated (gene expression) in tumor as compared to control 
samples. Timp3 is an inhibitor of the matrix metalloproteinases, a group of peptidases involved in 
degradation of the extracellular matrix (ECM) and is hypermethylated in gastric cancer. 
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4.7  Associating DNA methylation with Histone marks Information 
	  
Histone modifications play an important role in mediating patterns of DNA 
methylation[162]. We thought it would be interesting to understand how this relation 
between histone modifications and DNA methylation provides us insight into the 
aberrant gene expression pattern in our tumor model. To investigate this relationship, 
we implemented the methodology to determine the overlap between 
enrichment/depletion of H3K4me3 and Pol II with the DNA methylation pattern at the 
gene promoter region in tumor samples compared to normal ones. Firstly, we 
computed the normalized (by library size) reads coverage (of H3K4me3 and Pol II) at 
the promoter region (+-1kb of TSS) in both tumor and control samples. We then used 
Mann Whitney non-parametric statistical test on these computed promoter regions to 
ascertain the genes showing significant enrichment/depletion of H3K4me3 and Pol II at 
the promoter regions (tumor v/s control). Thereafter, log2 fold change (of histone mark 
enrichment/depletion) is computed between tumor v/s control to give quantitative 
score to these changes. Finally, this quantitative histone information was mapped to the 
differential methylation information for each gene. Only the genes hyper-methylated by 
more than 20 % and displaying significant alteration in histone modification enrichment 
was considered for the analysis. We observed stronger overlap between alterations in 
histone modification enrichment and DNA methylation changes in tumor [Figure 20]. 
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Eventually, we selected 316 genes classified based on the epigenomics data relations: 
Group 1 consisting of all genes hypermethylated in promoter and down-regulated in 
gene expression; Group 2 consisting of all genes hypermethylated in promoter and 
down-regulated in H3K4me3 or Pol II; Group 3 consisting of all genes that are down-
regulated (gene expression), whose promoters are hyper-methylated and shows 
H3K4me3 and Pol II depletion in tumor as compared to control samples. These 
candidate tumor suppressor genes are presently being screened in-vivo by sh-RNA 
library for experimental validation. 
 
 
  
Figure 20: Association of DNA methylation with histone modifications 
The figure represents the log2 fold change of H3K4me3 (left panel) and Pol2 (right panel) for tumor sample 
v/s control samples. 
	   73	  
5. Epigenomic and genomic determinants of RNA methylation 
	  
5.1 Background 
	  
The role of epigenetic modifications of histones and DNA has been extensively studied 
in various biological contexts but similar studies about the RNA modifications are still 
in nascent stage. The N6-methyladenosine (m6A) is the most abundant RNA 
modification whose genomic distribution and biological significance has only recently 
been researched [163]. This modification is laid down by a multi-component 
methyltransferase complex comprising of methyltransferase-like 3 (METTL3), METTL14 
and Wilms tumor 1-associating protein (WTAP). The m6A modification can be removed 
by α-ketoglutarate-dependent dioxygenase FTO and alkylated DNA repair protein alkB 
homolog 5 (ALKBH5).  The presence of m6A RNA demethylation and demethylases 
illustrates that m6A modification is dynamic and reversible in nature similar to other 
epigenetic modifications. Till now, two YTH domain-containing proteins, YTHDF2 and 
YTHDC1, have been identified as the readers of m6A-modification. YTHDF2 mediated 
mRNA degradation is dependent on methylation of target RNAs and thereby regulates 
mRNA stability and localization. Mutational studies and transcriptome-wide profiling 
of m6A have revealed RRACU as its primarily modified consensus sequence. This 
modification is mostly enriched around stop codons, in 3’ un-translated regions (3’ 
UTRs) and within long internal exons. Moreover, it affects various components of RNA 
metabolism including translation, splicing, RNA stability, transport and localization. 
Till now the primary mechanism suggested for its biological roles is the modulation of 
the RNA-protein interaction. The key components associated with the establishment 
and regulation of m6A are enriched in nuclear speckles. In this environment rich in 
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components of the splicing machinery they could directly interact with nascent RNA 
[127]. On the other hand, the role of other epigenetic marks, such as DNA methylation 
and histone post-translational modifications in the splicing mechanism and 
transcription modulation has been well established. So we investigated the possible 
associations between RNA methylation and epigenomics or regulatory proteins by 
integrative analysis of publicly available datasets of some of the cell lines that are 
profiled for RNA methylation. We focused on the human embryonic stem cell (H1) for 
which base-resolution DNA methylation data; a number of histone marks, and 
transcription factors data are available. In addition we also used data from the mouse 
embryonic fibroblast (MEFs) cell lines for which low-resolution MeDIP-seq (DNA 
methylation) data are available. 
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5.2 Materials and Methods 
 
5.2.1 Source of the publicly available datasets 
	  
RNA methylation data for the MEF cells: RNA methylation peaks were retrieved for 
GSM1518036 GEO sample, and specifically from the GSE61995_final_peaks.xlsx file 
available on the corresponding GSE61995 GEO series[131]. 
DNA methylation data for the MEF cells: MeDIP-seq peaks were retrieved from the 
GSM886553 GEO sample; peaks were called using MACS on mm9 by the authors[133]. 
CTCF peaks for MEF cells: ChIP-seq peaks for CTCF were retrieved from the 
GSM918743 GEO sample; peaks were called using MACS on mm9 by the authors as 
part of the mouse ENCODE project[164]. 
RNA methylation data for the H1 cells: RNA methylation data were downloaded for 
the GSM1272365 (H1 m6A) and GSM1272366 (input) GEO samples; the corresponding 
SRR1035222.sra and SRR1035221.sra files containing MeRIP-seq raw reads were 
retrieved from the SRA for H1 m6A and input, respectively[130]. 
DNA methylation data for the H1 cells: the H1 whole-genome bisulfite data available in 
the ListerEtAlBSseq Bioconductor package were considered[72]. 
Histone marks and TF ChIP-seq data for the H1 cells are downloaded from ENCODE 
project.
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5.2.2. Processing of public data 
	  
MEF m6A released peaks coordinates were mapped to mm10. Peaks were consequently 
moved to mm9 using the LiftOver UCSC online tool. 
H1 m6A peaks from[130] were called again from the raw data. Sra files were converted 
to fastq files using the fastq-dump tool. Raw reads were aligned to the hg18 genome 
using topHat (version 2.0.6) with default settings for un-stranded data and single-end 
reads[165]. Peaks were called on the resulting BAM files (H1 m6A vs input) using 
MACS (version 2.0.9) using default settings and the --auto-bimodal flag[166]. 
Histone marks and H1 TF ChIP-seq data were converted to hg18 using the liftOver tool 
implemented in the rtracklayer Bioconductor package. 
 
5.2.3. Integration with low-resolution DNA methylation data 
	  
Mouse TSS coordinates were identified using the TSS method of the compEpiTools 
Bioconductor package, based on the mm9 TxDb Bioconductor metadata package 
containing transcripts definitions. mm9 CpG Islands coordinates were obtained from 
UCSC using the rtracklayer Bioconductor package. 20Kbp regions centered at the mm9 
TSS coordinates were considered (55419 regions), and within this set we identified 2230 
regions overlapping with m6A and DNA methylation peaks in MEF cells 
(overlap>=1bp).  
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5.2.4. Integration with base-resolution DNA methylation data 
	  
H1 m6A peaks mapping to autosomal and sex chromosomes were retained. The 
summit (point of highest MeRIP-seq enrichment) was determined using the 
GRcoverageSummit from the compEpiTools package. m6A summits were divided into 
intragenic, intergenic and promoter summits using the GRannotateSimple from the 
compEpiTools package. Intergenic peaks were further filtered removing those summits 
laying closer than 5Kbp to an hg18 genebody. Peaks into exons and 3’UTRs were also 
identified based on the information extracted from the TxDb hg18 Bioconductor 
package. Exons matching 3’UTRs are removed from the exons set. At the same time, 
random exons and 3’UTRs were identified, sampling from the overall set of exons and 
3’UTRs not associated with m6A a number of regions equal to the number of those 
associated with m6A. 4Kbp regions centered at the m6A summit were defined. 
The m6A enrichment reported in Figure 22 is determined using the compEpiTools 
package (normalized number of reads in the m6A IP subtracted of the normalized 
number of reads in the control sample; where normalized indicates that is divided by 
the total number of aligned reads in the corresponding BAM file). 
Absolute and relative DNA methylation within these 4Kbp regions (divided in 20 
equally sized bins) were determined using the methylPipe Bioconductor package, 
focusing on cytosine positions covered by at least 5 reads reading C (unconverted by 
bisulfite, thus supporting the methylation call), and binomial corrected p-value lower 
than 0.01. Intragenic regions and those mapped to promoters, exons and 3’UTRs for 
genes on the minus strand were reverted, so that the signal -2Kbp upstream the m6A 
peaks indicate the signal on the 5’ of the RNA methylation event. 
	   78	  
 
5.2.5. Prediction of m6A peaks from epigenetic and regulatory features 
	  
To measure how much (epi) genomic features are predictive of m6A we used m6A 
peaks and ENCODE datasets of histone marks and regulatory proteins for H1 cell lines. 
Before building a model, it was imperative to generate a simulated dataset 
(representing background) of the m6A-regions. The majority of m6A peaks lies in exon 
regions (nearly 70%). To consider the genomic prevalence of this modification we 
generated m6A- regions by random sampling of exon regions not overlapping with 
m6A peaks. This would mean that no genomic composition bias is included while 
comparing foreground (m6A+) and background regions (m6A-). We had 28871 m6A 
peaks (m6A+) and 28871 random exon regions devoid of any m6A peaks (m6A-), 
totaling 57742 genomic regions. These genomic regions were limited to a length of 288 
bases determined from the average length of m6A peak. m6A+ regions co-ordinates are 
defined as ± 144b from the m6A peak summit whereas m6A- regions co-ordinates are 
defined as ± 144b from the midpoint of random exon region. We also added CpG island 
information and RRACT motif information to these set of features. A classification 
matrix was computed representing the presence or absence (1 or 0) of the associated 
(epi)genomic features. Only DNA methylation values was represented in continuous 
numerical scale determined as relative methylation level by profileDNAmetBin function 
of methylPipe. The association of each of the marks with m6A positivity was assessed 
using univariate logistic regression and penalized linear regression method LASSO. 
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5.3 Results 
 
5.3.1 RNA and DNA methylation 
	  
In order to evaluate if RNA methylation peaks (m6A) could be associated to any 
corresponding pattern on the methylation of DNA (5-methyl cytosine, 5mC), we looked 
for high-throughput experiments profiling these data types in the same cell type. We 
were able to identify two independent studies profiling m6A and 5mC in mouse 
embryonic fibroblast (MEF) cells[131, 133], and other two independent studies 
analyzing these marks in human embryonic stem cells (H1 cell line)[72, 130]. While both 
studies profiled m6A using the MeRIP-seq methodology, DNA methylation was 
profiled in the MEF cells using the MeDIP-seq methodology (providing low-resolution 
data) and in the H1 cells using whole-genome bisulfite sequencing (providing base-
resolution data). 
 
5.3.2 Integration with low-resolution DNA methylation data 
	  
RNA and DNA methylation peaks in MEF cells were retrieved from the original 
publication, and accounted for 10167 and 187860 peaks, respectively. For a first 
qualitative analysis on the patterning of these two marks, we focused on 20Kbp 
genomic regions centered at mouse TSS, including the genomic counterpart for most of 
the expected m6A sites (5’UTRs and the longest internal exons). We specifically selected 
those regions containing peaks for both marks (2230 regions), and RNA and DNA 
methylation peaks within these regions are displayed in Figure 21 together with CpG 
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Islands (CGIs) and gene annotation. Considering that each region was divided into 20 
bins (1Kbp/bin), the spearman correlation for all the m6A and 5mC bins in all the 
regions is 0.35. When these two marks are co-occurring, their patterning is remarkably 
similar, as is the correspondence with the exons.  
Both m6A and 5mC are implicated in splicing processes[127, 132], but no evidence of 
joint action of these marks in this process has been reported yet. We reasoned that 
genomic enrichment of 5mC within the same exons marked by m6A in the 
corresponding transcripts could be relevant for proper RNA splicing, and we 
speculated that the exons in the 2230 regions where m6A and 5mC are co-occurring and 
highly correlated might represent a set of genes whose splicing is actively controlled. 
Several regulatory proteins are involved in the control of splicing mediated by DNA 
methylation, including CTCF, MeCP2 and HP1, and we could identify an ENCODE 
ChIP-seq experiment targeting CTCF in MEF cells[164]. Overall, taking into account 
exons not simultaneously marked by m6A and 5mC, only 7% of them are associated to 
CTCF in MEF cells. The same proportion of exons is associated to CTCF even when 
restricting this set to the exons marked by 5mC MeDIP peaks. Rather, when focusing on 
the exons that are marked by both m6A and 5mC, 14% of them are associated with 
CTCF, thus supporting the idea that DNA methylation and RNA methylation co-occur 
since they are cooperatively involved in active splicing of these transcripts. 
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5.3.3. Integration with base-resolution DNA methylation data 
 
There are two possible reasons for the high density of 5mC events in correspondence of 
m6A marks: (i) there is an increased frequency of 5mC out of the total number of 
cytosines possibly methylated, or (ii) there is an increased density in the total number of 
Figure 21: Association of m6A peaks with MeDIP-seq DNA methylation peaks in MEF 
cells. 
Each row of the heatmap refers to a 20Kbp mouse genomic region, centered at a mouse TSS, 
containing at least one m6A peak and one MeDIP-seq peak. Each region is divided in 20 equally 
sized bins. For the m6A and MeDIP-seq tracks, a bin is colored in red if it matches a peak of the 
corresponding data type. For the CGI track, red bins indicate the presence of CpG Islands. For the 
gene + and gene – tracks, red bins indicate exons and pink bins indicate introns on the forward and 
reverse strand, respectively. 
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cytosines possibly methylated. These two scenarios are not mutually exclusive, and 
MeDIP-seq data do not easily allow shedding light on this point[147, 167]. To clarify 
this aspect and explore DNA methylation patterns at the base-level in correspondence 
of m6A peaks, we took advantage of the availability of RNA methylation and base-
resolution DNA methylation data in human H1 cells[72, 130]. 
We could identify 28872 m6A peaks in H1 cells by re-analyzing MeRIP-seq raw 
data[130]. We stratified these peaks into different genomic functional units, including 
intergenic regions, promoters, intragenic regions, exons, and 3’UTRs. For each m6A 
peak, we considered a 4Kbp region centered at the peak summit, and we determined 
MeRIP-seq enrichment together with average absolute (mC/bp) and relative (mC/C) 
DNA methylation profiles. We considered 5mCs in both the CpG and non-CpG context 
(divided in CHG and CHH, where H is any DNA base but G), since they are all highly 
frequent in embryonic stem cells[72, 141]. The CpG content (mC/bp in the CpG context) 
increases at the level of the m6A peak for all these regions. While the density of 5mCs 
follows the increasing CpG density in all the considered regions with the exception of 
the promoter, the resulting relative DNA methylation (mC/C) indicates that the 
number of 5mCs does not keep up with the number of potential sites particularly in 
promoter regions and exons [Figure 22]. While for the promoter regions this might be 
expected, this is not necessarily the case for exons. This finding is not in contrast with 
the result obtained in MEF cells, since the observed increasing density for the 
mCpG/bp mirrors the analogous trend observed for the MeDIP-seq signal in MEF cells. 
Complimentary to the pattern of increased mCpG density described in mouse (and 
confirmed in human), the base-resolution analysis of 5mCs in the CpG context in 
human reveals incomplete DNA methylation of the CpGs. This depletion might suggest 
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that the regions that are marked by m6A in the transcripts are interaction spots for 
specific regulatory proteins on the genome. Interestingly, the same pattern of depletion 
of mCpGs reported for promoters and exons can be found for 5mCs in the non-CpG 
context in all considered regions [Figure 23]. Differential patterning between 5mCs in 
these two contexts were already reported, suggesting different functionality and control 
of these marks[72, 141]. Importantly, all these patterns of 5mC depletion in the CpG and 
non-CpG context are specific for exons and 3’UTRs associated with m6A peaks, and 
cannot be found in control exons and 3’UTRs devoid of that mark. 
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m6As were found to be predominantly associated to adenosines in the RRACT 
context[127], where R could match with either G (more frequent for this motif) or A. We 
took advantage of the base-resolution DNA methylation data to explore the genomic 
prevalence of 5mC in correspondence of the C within the motif (a potential non-CpG 
methylation site), and in the bases surrounding the motif occurrences. 20120 m6A peaks 
can be associated to the RRACT motif on the genome, and in case of multiple 
occurrences we focused on the motif that is closest to the m6A peak summit. We 
considered a 20bp region centered on the motif cytosine, and we counted for each 
position the number of 5mCs normalized for the total number of potential 5mC sites, 
stratifying by sequence context (Figure 23A). In general, 36% of the m6A peaks 
associated with RRACT have at least one 5mC. The methylation levels of CpGs are 
remarkably depleted at RRACT sites associated with m6A peaks in correspondence to 
those not associated with m6A peaks (compare Figure 23B with Figure 23C). 
 
 
Figure 22: Broad depletion of DNA methylation in correspondence of m6A peaks in 
H1 cells. 
MeRIP-seq enrichment (blue lines) in 4Kbp regions centered at the m6A peak summit in H1 cells 
is stratified by a set of human genomic functional units. For each functional unit, the absolute 
density of 5mC events (mC/bp), the density of potential DNA methylation sites (C/bp), and the 
relative DNA methylation (mC/C) are determined for 20 equally sized bins. 5mC in different 
sequence context (CG, CHG and CHH, where H is any base but G) are separately plotted. 
Random exon regions do not contain m6A peaks and their number matches the number of exon 
regions containing m6A peaks. Random 3’UTR regions do not contain m6A peaks and their 
number matches the number of 3’UTR regions containing m6A peaks. Each data series in these 
plots is normalized dividing by each series maximum value. 
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Figure 23: Depletion of DNA methylation around the RRACT m6A motif in H1 cells. 
(A) The count of 5mC events, in a given sequence context (CG, CHG or CHH, where H is any base but 
G) and for a given DNA strand, is determined for each human genomic base in 20bp genomic regions 
centered at the RRACT motif associated to a m6A peak. (B) For each base the relative methylation is 
determined dividing the data reported in panel (A) by the number of regions having a potential DNA 
methylation site of the considered context at that position and strand. (C) As in panel (B) but for an equal 
number of random 20bp regions containing the RRACT motif not matching any H1 m6A peak. 
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5.4 Association of m6A with various epigenomics and regulatory features 
 
To investigate the association of (epi) genomic and regulatory features with m6A used 
different kinds of analysis were used: multivariate analysis and univariate analysis. The 
analysis was performed in collaboration with Dr. Lara Lusa (Biostatistician, University 
of Ljubljana). The multivariate analysis performed using penalized linear regression 
method LASSO builds a model to test combined predictive ability of 
epigenomics/regulatory features to m6A positivity. A 5-fold cross-validation analysis 
was performed to test the classification ability of this model. The cross validation AUC 
of the model built using LASSO was about 0.70 [Figure 24].  
 
 
 
 
 
 
 
 
 
The cross-validation curves indicate that it would not be possible to achieve a large 
sensitivity (true positive rate) without making several false positive assignments. For 
Figure 24: AUC curves obtained from LASSO method 
	   87	  
example, in order to achieve an approximately 90% accuracy for the prediction of m6A+ 
samples, one would expect a 20% accuracy for the m6a- samples (0.80 false positive 
rate), indicating that most of the m6a+ samples would be predicted correctly, but most 
of the m6a- samples would be misclassified.  Hence, the multivariate model built by 
combining all the features was not strong enough to properly classify m6A presence or 
absence.  
We then performed univariate analysis using logistic regression to determine the 
association of individual feature with m6A positivity. Further we selected the top 
ranking marks according to the odds ratio determined by univariate regression [Table 
3]. Interestingly, RRACT (binding motif of m6A modification) was not good in 
predicting m6a+ and many other variables performed better. Next we examined the 
association of these top-ranking marks with the m6A peaks using various plots. 
 
Marks	   A)	  Neg.	  
Marker	  
B)	  Pos.	  
Marker	   C)	  Total	  
Numbers	  
D)	  RR	   E)	  OR	   F)	  UL	   G)	  LL	  
ZNF274 
0.47 0.93 284.00 1.98 14.91 23.49 9.47 
E2F6 
0.45 0.74 3905.00 1.64 3.43 3.69 3.18 
CGI 
0.43 0.72 7604.00 1.66 3.30 3.48 3.13 
CTBP2 
0.47 0.73 888.00 1.57 3.13 3.63 2.69 
CHD1 
0.47 0.72 1464.00 1.55 2.95 3.31 2.63 
KDM4A 
0.42 0.68 11301.00 1.62 2.90 3.03 2.77 
RBBP5 
0.46 0.71 2931.00 1.55 2.87 3.12 2.65 
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POLR2ApS5 
0.46 0.67 3149.00 1.47 2.44 2.64 2.26 
POLR2A 
0.46 0.67 3882.00 1.47 2.44 2.62 2.28 
EZH2 
0.47 0.68 608.00 1.45 2.43 2.88 2.05 
SAP30	  
0.43	   0.65	   10783.00	   1.51	   2.42	   2.53	   2.32	  
TAF7	  
0.46	   0.68	   1933.00	   1.45	   2.40	   2.64	   2.18	  
TAF1	  
0.46	   0.67	   3428.00	   1.46	   2.40	   2.58	   2.23	  
CREB1	  
0.46	   0.67	   3074.00	   1.45	   2.36	   2.55	   2.19	  
GTF2F1	  
0.47	   0.67	   805.00	   1.44	   2.35	   2.72	   2.02	  
H3K9ac	  
0.40	   0.60	   19896.00	   1.53	   2.33	   2.41	   2.24	  
RFX5	  
0.47	   0.67	   141.00	   1.43	   2.32	   3.29	   1.63	  
SIN3A	  
0.46	   0.66	   3475.00	   1.44	   2.31	   2.49	   2.15	  
TBP	  
0.46	   0.66	   2776.00	   1.44	   2.31	   2.50	   2.13	  
BACH1	  
0.47	   0.67	   945.00	   1.43	   2.28	   2.61	   1.99	  
REST	  
0.47	   0.67	   622.00	   1.42	   2.26	   2.68	   1.91	  
JUND	  
0.47	   0.66	   1141.00	   1.42	   2.25	   2.55	   1.99	  
PHF8	  
0.41	   0.61	   16346.00	   1.48	   2.23	   2.32	   2.15	  
RRACT	  
0.48	   0.51	   39664.00	   1.05	   1.1	   1.14	   1.06	  
 
Table 3: Variable association with m6A.  The table reports, for each of the marks: A) the 
proportion of m6A+ samples in the group of samples with negative marker (mark not present), 
B) the proportion of m6A+ samples in the group of samples with positive marker (mark 
present), C) Total number of occurrences of these marks at the m6A positive regions, D) RR is 
defined as the ratio of the two proportions (proportion of m6A+ samples in the positive marker 
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group divided by the proportion of m6A+ samples in the negative marker group), E) The OR is 
defined as the ratio of the odds for m6A+ in these groups, F)UL and G) LL denotes the upper 
and lower limit of the 95% confidence intervals for the OR respectively (estimated with 
univariate logistic regression, where the outcome is m6A positivity and the covariate is the 
marker). OR=1 indicate that the probability of being m6A+ is the same in the group of marker 
positive and negative samples. OR>1 indicate that marker positive samples have a larger 
probability of being m6A+ compared to marker negative samples, OR<1 that marker negative 
samples have larger probability of being m6A+ compared to marker positive samples. Large 
confidence intervals are observed for markers that have a low positivity proportion. 
 
5.4.1 Combinatorial association and overlap with TSS regions 
	  
To investigate the patterning of our top rankings features with RNA methylation 
events, we generated heatmaps of the m6A+ regions marked by the top rankings 
features (determined by odds ratio). Separate heatmaps were drawn for features having 
extensive overlap (associated with thousands of m6A peaks) and those with few 
overlaps (associated with hundreds of m6A peaks) with m6A peaks. Further, these 
regions are annotated according to overlaps with the TSS: leftmost TSS, internal TSS, no 
TSS and 3’ UTRs. The region defined for overlap was m6A peaks summit (+-144b) same 
as the one used for LASSO model building.  
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The heatmap for features having few overlaps with m6A peaks (associated with 
hundreds of m6A peaks) displays that the binding of these marks is mutually exclusive 
in genome (in regions marked by m6A) [Figure 25A].  Similarly, most of the features of 
the other group (associated with thousands of m6A peaks) also show mutual exclusivity 
in binding albeit not of same degree as the other [Figure 25B]. Within our top rankings 
features were a set of marks associated with Pol2 machinery: POLR2Ap5S, POLR2A, 
TAF7, TAF1 and TBP. The heatmap of these features show nice overlap in their binding 
pattern with each other [Figure 26A]. Although a majority of the overlap exists in 
regions around the TSS (where it is mostly expected), interestingly a good number of 
these overlap exists in regions away from TSS as well. All these heatmaps (the three 
Figure 25: Heatmaps of top ranking features. 
A) Patterns of selected marks with few hundred events corresponding with m6A peaks. B) Patterns of 
selected marks with thousands of events corresponding with m6A peaks. 
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different groups) show that the majority overlaps of these features are at the genomic 
regions closer to the TSS. A protein-protein interaction map displaying interaction 
between components of Pol2 and the RNA methylation machineries was obtained using 
STRING database [Figure 26B]. It displays that the major component of RNA 
methylation machineries METTL3 and METTL4 (writers of m6A modification) shows 
interaction with Pol2 machinery. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 26: Pol2 and RNA methylation machinery. 
A) Patterns of components of the Pol2 machinery corresponding with m6A peaks. B) Protein-protein 
interaction between components of the Pol2 and the RNA methylation machineries. 
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To further examine the spatial association of the top ranking marks and m6A peaks, we 
plotted reads density of these features around (+-1kb) of m6A peaks summit [Figure 
27A]. Most of the marks show increase in the enrichment (reads coverage) around the 
m6A peak summit while some remain uniformly enriched throughout the defined 
region. ZNF274 shows sharp increase in enrichment at the m6A peak summit and also 
marks of the Pol2 machinery have nice overlap in the enrichment at these regions. These 
plots quantitatively confirm the prevalence of these marks around the m6A-binding 
region (summit) as previously shown by the heatmap analysis. A similar pattern 
emerged at the regions of m6A peaks distal from TSS implying this association is not 
driven by the proximity to TSS [Figure 27B]. 
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Figure 27: Spatial association between selected marks and m6A peaks. 
A) Spatial relationship between selected marks and all m6A peaks. B) Spatial relationship between 
selected marks and m6A peaks distal from TSS. 
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5.5 Marks associated with transcriptional repression 
	  
Many studies have described the influence of m6A mark on nearly all aspects of RNA 
metabolism [127]. The two mechanisms currently ascribed to define the function of 
m6A mark are: a) recruitment of proteins or b) bringing conformational changes in 
RNA[163]. The underlying theme behind both mechanisms is m6A binding altering the 
RNA-protein interaction. The binding of m6A could either make an effector protein 
bind to those transcripts or could alter sequence specific binding of other proteins in its 
vicinity. One such example is YTHDF protein (which binds to m6A) mediated decay of 
transcripts that requires methylation of RNA and could be dynamically regulated by 
methylation or demethylation mechanisms[168]. Furthermore, the levels of m6A 
modification have been inversely correlated with mRNA stability implying its role as a 
transcriptional repressor[169]. Additional reader proteins might also exist that affect 
various components of RNA metabolism. So it was interesting to find many top 
rankings features having roles in biological phenomenon such as transcriptional 
repression, splicing, chromatin modification and RNA Pol II machinery [Figure 28]. We 
discuss below some of these interesting features.  
 
 
 
 
 
	   95	  
 
 
 
 
 
 
 
 
 
 
Zinc Finger Protein 274 (ZNF274) has highest association with m6A+ peaks. 
Although it has only 284 occurrences (among the total tested regions), 93% of these 
regions co-occur with m6A. We also explore this association in HepG2 cells [Figure 29] 
and HeLa cells and observed similar overlap between m6A and ZNF274. ZNF274 is 
suggested to play the role of a transcriptional repressor. H3K9me3 is one of the histone 
modification associated with gene silencing especially zinc finger genes[170]. SETDB1 
and G9a histone methyltransferases are involved in mediating this process[170]. 
SETDB1 is recruited to specific genomic locations via interaction with the co-repressor 
TRIM28 (KAP1), which is in turn recruited to the genome via interaction with ZNF274 
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Figure 28: Biological process of top rankings marks. 
Each	  bar	  represents	  odds	  ratio	  of	  association	  of	  each	  feature	  with	  m6A	  mark.	  The	  
top	  features	  identified	  by	  odds	  ratio	  are	  enriched	  in	  biological	  processes	  to	  which	  
the	  role	  of	  m6A	  has	  also	  been	  assigned.	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[170]. Eventually SETDB1 promotes the increase of H3K9me3 at the 3' ends of zinc 
finger genes leading to their transcription repression[170].  
 
 
 
 
 
 
 
 
 
 
E2F6 is a transcriptional repressor [171] binding to 3905 regions in H1, co-occurring 
with m6A peaks in 74% of cases. It regulates a subset of E2F-dependent genes whose 
products are required for entry into the cell cycle (but not for normal cell cycle 
progression). It may silence expression via the recruitment of a chromatin remodeling 
complex containing histone H3K9 methyltransferase activity[172]. Similarly, CTBP2 is a 
co-repressor targeting diverse transcription regulators. In H1, it binds to 888 regions, co-
occurring with m6A peaks in 73% of cases. CHD1 is a chromatin-remodeling factor that 
function as substrate recognition component of the transcription regulatory histone 
Figure 29: Overlap of ZNF274 with m6A in HepG2 cells. 
The	  figure	  displays	  density	  of	  ZNF274	  reads	  around	  the	  region	  of	  m6A	  peaks	  summit	  in	  
HepG2	  cells.	  It	  represents	  association	  of	  ZNF274	  at	  the	  m6A	  peak	  sites.	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acetylation (HAT) complex SAGA. In H1, it binds to 1464 regions, co-occurring with 
m6A peaks in 72% of cases. It functions to modulate the efficiency of pre-mRNA 
splicing in part through physical bridging of spliceosomal components to 
H3K4me3[173].  
KDM4A also known as JMJD2A demethylates H3K9me3 and H3K36me3. In H1, it 
binds to 11301 regions co-occurring with m6A peaks in 68% of cases. The protein 
belongs to a family that includes the ALKBH5 and the FTO RNA demethylases [174]. It 
participates in transcriptional repression of ASCL2 gene (an imprinted gene essential 
for proper placental development) by targeting the N-CoR complex[175]. RBBP5 is a 
ubiquitously expressed nuclear protein that binds directly to retinoblastoma protein 
thereby regulating cell proliferation. In mouse embryonic stem (ES) cells it plays a 
crucial role in differentiation along the neural lineage by regulating gene induction and 
H3K4 methylation at key developmental loci[176]. 
SAP30 is a component of histone deacetylase complex. “It is involved in the 
functional recruitment of the Sin3-histone deacetylase complex (HDAC) to a specific 
subset of N-CoR corepressor complexes”[177]. SIN3A acts as a transcriptional co-
repressor utilized by the Mad-Max family of DNA-binding transcriptional 
repressors[178].  It is also recruited by PER complex to repress Per1 transcription 
thereby modulating circadian rhythm[179]. Similarly various circadian RNAs contain 
the m6A modification and inhibition of this modification increase nuclear time 
exit[180]. SIN3A is also recruited by REST to carry out transcriptional repression of 
neuronal genes[181]. REST is a transcriptional repressor binding neuron-restrictive 
silencer element (NRSE) and repressing neuronal gene transcription in non-neuronal 
cells[181]. In H1, it binds to 622 regions, co-occurring with m6A peaks in 67% of cases. It 
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restricts the expression of neuronal genes by associating with two distinct corepressors, 
mSin3 and CoREST, which in turn recruit histone deacetylase to the promoters of REST-
regulated genes[182]. In addition to the above mechanism, it also mediates repression 
by recruiting the BHC complex at RE1/NRSE sites [183]. 
Out of these features currently follow up experimental validation (in collaboration 
with Dr. Bruno Amati Lab) is being carried out on ZNF274 by knockdown studies. 
ZNF274 has the highest association with the m6A marks and its role as a transcriptional 
repressor has been well established. The knockdown experiment will determine if 
lowering of its expression reduces the m6A methylation levels in the targeted mRNAs.  
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Discussion 
 
The field of epigenomics is rapidly progressing with new information coming out from 
multiple studies and various international consortia. The massive amount of genome-
wide data accumulated presents computational challenges owing to the complex nature 
of relationship of the various components of epigenetics. These players act in a 
coordinated and combinatorial way to modulate various biological processes.  To 
understand the complexity of cross talk of these components it is imperative to develop 
computational methods that can perform integrative analysis of all these datasets 
though conscious of the biases of technologies profiling them.  There are many tools 
available catering specifically to different technologies but a common platform for 
integrative analysis was missing. Considering this lacuna we intended to develop 
specific methods that can efficiently handle whole genome base-resolution DNA 
methylation datasets and perform integrative analysis with other epigenomics 
component.  
The methylPipe and compEpiTools companion libraries offer a comprehensive 
system for the integrative analysis of heterogeneous epigenomics data types. 
methylPipe provides a set of classes, methods and functions that are tailored to DNA 
methylation high-throughput data, while accommodating data highly different in terms 
of resolution and genome coverage. To our knowledge, methylPipe is the first software 
package allowing the analysis and manipulation of multiple WGBS experiments while 
also being compatible with targeted or low-resolution DNA methylation experiments. 
Furthermore, compEpiTools includes a series of methods and functions that are 
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commonly used in the integrative analysis of epigenomics, genomics and regulatory 
datasets. Importantly, compEpiTools is compatible with methylPipe classes thus 
allowing an effortless combination of these data with other epigenomics data. Lower-
level versions of few of these functionalities are already available albeit dispersed in 
various Bioconductor packages, such as the routines for counting reads. For these tasks 
methylPipe and compEpiTools provide simplified and more homogeneous access to 
lower-level routines, adding an extensive number of new functionalities for DNA 
methylation and other epigenomics and regulatory data types. Altogether, this suite of 
packages provides a clear reference entry-point for scientists focusing on the analysis of 
epigenomics data. This set of tools is currently being successfully used to build 
pipelines for the most common omics data types. Even more importantly, in our hands 
this approach is proving to be an excellent resource to effectively provide to 
experimental scientists with very basic R skills a complete toolkit for the comprehensive 
analysis of their own generated data. In conclusion, the Bioconductor-compliant 
methylPipe and compEpiTools packages provide a comprehensive suite of tools for the 
integrative analysis of epigenomics data, covering most of the functionalities commonly 
required in the joint analysis of DNA methylation and epigenomics data.  
We applied these methods to identifying novel tumor suppressor genes. New 
tumor suppressor genes identified in this project shall shed new light on the genes, 
pathways and mechanisms that are critical for Myc-induced lymphomas. The Eµ-myc 
model is ideally suited not only for the gene discovery phase of this project but also for 
the dissection of the cellular and molecular events that underlie tumor progression. The 
relevance of the genes and pathways identified will be addressed in human samples. 
Finally, an important translational objective is to understand whether and how we may 
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specifically re-activate altered tumor suppressor pathways through pharmacological 
approaches in order to curb tumor progression. 
Epigenetic modifications on DNA and histones are subjected to reversible 
regulation affecting cell differentiation and development. Recently, the writers and 
erasers of N6-methyladenosine (m6A) the most abundant RNA modification have been 
identified illustrating the possibility of its regulation in different biological contexts. Its 
role in various aspects of RNA metabolism has already been illustrated. However, no 
study has looked at the association of this post-transcriptional modification with 
epigenomics components and regulatory features. In our study we investigated the 
possible associations between RNA methylation and epigenomics or regulatory 
proteins by integrative analysis of publically available datasets of some of the cell lines 
that are profiled for RNA methylation.  
First we evaluated the association of RNA methylation peaks (m6A) to the 
corresponding pattern on the methylation of DNA (5-methyl cytosine, 5mC) in MEF 
cells. The statistical results show low correlation (spearman correlation 0.35) between 
the two features but the patterning was remarkably similar at co-occurring regions 
especially at the exons. Since, both m6A and 5mC are implicated in splicing processes 
we hypothesize that genomic enrichment of 5mC within the same exons marked by 
m6A in the corresponding transcripts could be relevant for proper RNA splicing. The 
low resolution MeDIP-seq data could not clarify if high density of 5mC events in 
correspondence of m6A marks is due to an increase in true 5mC events or an increase in 
potential methylation site (increased CpG density).  To shed light into it we explored 
DNA methylation patterns at the base-resolution in correspondence of m6A peaks in 
human H1 cells. The base-resolution analysis of 5mCs in human reveals incomplete 
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DNA methylation of the CpGs which might suggest m6A binding sites in transcripts as 
interaction spots for specific regulatory proteins on the genome. Importantly, depletion 
was specific for exons and 3’UTRs associated with m6A peaks but not in random exons 
and 3’UTRs devoid of that mark. Since the predominant consensus sequence of m6A 
enrichment is RRACU, we further explored the genomic prevalence of 5mC in 
correspondence of the C within the motif and the bases surrounding the motif 
occurrences. The methylation levels of CpGs are remarkably depleted at RRACT sites 
associated with m6A peaks in correspondence to those not associated with m6A peaks.  
To investigate the association of (epi) genomic and regulatory features with m6A 
we performed multivariate LASSO analysis and univariate logistic regression analysis. 
The model built using LASSO was not strong enough to classify the m6A presence or 
absence. Hence, we focused our attention to univariate analysis to identify individual 
features associated with m6A peaks. Among them, DNA methylation was the top 
ranking predictor of m6A (associated with lower level of DNA methylation). On the 
contrary RRACU motif was not among the top rankings features. We then investigated 
the combinatorial association of the top rankings features determined by odds ratio 
with m6A marked regions. It showed mutually exclusive binding patterns of a number 
of features apart from the components of Pol2 machinery that were showing nicely 
overlapping binding patterns. Further examination of the spatial association of these 
features (using reads density) and m6A peaks quantitatively confirmed these findings.  
Numerous studies have described the role of m6A mark on several RNA 
metabolism processes primarily by altering the RNA-protein interaction. The important 
challenge ahead is to elucidate the underlying mechanism and players carrying out this 
role. The first step towards it would be to identify additional reader or participatory 
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proteins that affects this mechanism. So in light of this it was interesting to find many 
top rankings features identified by us having roles in biological phenomenon such as 
transcriptional repression, splicing and chromatin modification. We are conducting 
follow up experimental validation on ZNF274 (a transcriptional repressor) that has the 
highest association with the m6A marks. We believe our study has provided a 
preliminary insight into the association of epigenetics modifications and RNA 
methylation and anticipate that the follow up studies will provide stimulus to this 
exciting new realm of research. 
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